Exploring Genetic Susceptibility to Autism Spectrum Disorders by Kantojärvi, Katri
Exploring Genetic Susceptibility to
Autism Spectrum Disorders
Katri Kantojärvi
UNIVERSITY OF HELSINKI
FACULTY OF MEDICINE
Katri Kantojärvi    Exploring G
eneti
c Suscepti
bility to A
uti
sm
 Spectrum
 D
isorders
ISBN 978-952-10-8694-6 (paperback)
ISBN 978-952-10-8695-3 (PDF)
Unigrafia OY
Helsinki, Finland 2013

EXPLORINGGENETICSUSCEPTIBILITYTO
AUTISMSPECTRUMDISORDERS
Katri Kantojärvi 
Department of Medical Genetics 
Haartman Institute 
University of Helsinki 
ACADEMIC DISSERTATION 
To be publicly discussed, with the permission of The Faculty of Medicine, 
University of Helsinki, in the lecture hall 2, Biomedicum Helsinki, 
on the 26th of April, at 12 o’clock noon. 
HELSINKI 2013 
The artwork on the cover page is drawn by a boy with childhood autism.  
Published with the permission of the Department of Child Neurology, Helsinki University 
Hospital and the parents of the child.  
ISBN 978-952-10-8694-6 (paperback)  
ISBN 978-952-10-8695-3 (PDF) 
Unigrafia OY 
Helsinki, Finland 2013 
Supervised by  
Docent Irma Järvelä  
Department of Medical Genetics 
Haartman Institute  
University of Helsinki 
Helsinki, Finland  
and 
Docent Päivi Onkamo 
Department of Biosciences 
University of Helsinki  
Helsinki, Finland 
Reviewed by  
MD, PhD Jacob Vorstman 
Department of Psychiatry   
University Medical Center Utrecht 
Netherlands 
and 
Docent Liisa Myllykangas 
Department of Pathology 
University of Helsinki and HUSLAB 
Helsinki, Finland 
Opponent
Professor Leena Haataja  
Department of Child Neurology 
Turku University Hospital 
Turku, Finland 
Everyone is a genius. But if you judge 
 a fish on its ability to climb a tree,  it will 
live its whole life believing that  it is stupid. 
-Albert Einstein
5ABSTRACT
Autism spectrum disorders (ASD) are neuropsychiatric disorders characterized by restricted 
repetitive behavior and abnormalities in communication and social interaction. Although the 
heritability of the trait has been estimated to be relatively high, the model of inheritance of 
ASD seems to be very complex and probably involves multiple interacting genes. Also, 
environmental factors together with genetic risk factors may increase the risk for autism. 
The purpose of this study was to detect genetic variants predisposing to ASD. We initiated 
the  study  with  fine  mapping  of  chromosomal  region  Xq11.1-q21.33  in  99  Finnish  ASD  
families where linkage has been observed in earlier studies. The highest multipoint LOD 
score was obtained with the marker DXS1225 at Xq21.1 (NPLall=3.43). However, Sanger 
sequencing of five candidate genes in the linkage region did not reveal any disruptive 
mutations. Despite that, in Study IV we detected significant association in a family-based 
genome-wide  association  (GWA)  scan  at  Xq21  in  the  PCDH11X gene. There are several 
candidate genes in the linkage region and exome sequencing of the X chromosome might 
reveal disruptive mutations in ASD.  
Aberrant glutamate metabolism has been observed in both ASD and obsessive compulsive 
disorder (OCD). In Study II we analyzed if single nucleotide polymorphisms (SNPs) previously 
associated in OCD in the glutamate transporter gene SLC1A1 at 9p24 are also associated in 
ASD. We further analyzed whether the SNPs reported earlier in the largest linkage study of 
ASD by the Autism Genome Project (2007) at chromosomal areas 9p24 (rs1340513 and 
rs722628) and 11p12-13 (rs1358054 and rs1039205) are associated with ASD in a sample of 
175 Finnish ASD cases and 216 controls. SNP rs1340513, in JMJD2C, the neighboring gene of 
SLC1A1, showed significant association with ASD in this study. In this thesis, the GWA scan 
(Study IV) and copy number variants (CNVs) with a different sample set also supported the 
association at locus 9p24 with SLC1A1, JMJD2C and PTPRD.
Synaptic defects have been suggested to be the mechanism underlying autism. Disruptive 
mutations in synaptic genes NRXN1, NLGN3/4X and SHANK2/3 have been detected in ASD 
patients. In Study III we continued the mutation screen of the SHANK2 gene in 455 European 
6ASD  families.  Several  harmful  mutations  were  detected  and  in  functional  analyses  we  
observed that they reduced synaptic density in vitro. We also detected deletions in the 
SHANK2 gene in ASD samples. We noticed that patients who had a SHANK2 deletion carried 
additional CNVs on chromosomal region 15q11-q13, which has previously been associated to 
ASD and several other neuropsychiatric disorders. This supports a multiple hit model for 
ASD. Additional studies are warranted to analyze how many mutations are sufficient to 
contribute to ASD and what kind of combination of genetic defects will be detected in 
individual ASD families. 
In this thesis, we performed a genome-wide scan with a novel sample set of 83 Finnish ASD 
families and 750 controls (a cohort of Health 2000 study). We detected the strongest 
association at chromosome 16p13.2 with the RBFOX1 gene, which regulates tissue-specific 
splicing of several autism related genes. Preliminary evidence of epistatic interactions was 
obtained between SNPs in NRXN1 and UBA52, as well as RBFOX1 and SCN1A, and DLG2 and
RBFOX3. In addition, we performed promoter analyses for ASD candidate genes and 
discovered a possible transcriptional regulatory site in the promoter area of AVPR1A, which 
might partly explain the associations with autism observed with the promoter 
polymorphisms of this gene. Furthermore, a transcription factor (TF) binding site for early 
growth response (EGR) was enriched in autism candidate genes. Finally, we performed CNV 
analyses and detected large (>400 kb) CNVs in chromosomal regions 15q13.3, 16p11.2, 
17q12 and 22q11. CNVs in the same regions have been detected in ASD and other 
neuropsychiatric disorders such as ADHD, epilepsy, schizophrenia and intellectual disability 
in earlier studies. We also observed CNVs in known ASD candidate genes for example DISC1, 
FOXG1, ASMT, PCDH11X, and PRODH.
In conclusion, the results obtained in this thesis show that several genetic risk variants 
predispose to ASD and epistasis between ASD candidate genes play an important role in 
these disorders. More studies are warranted to explore the combination and interaction of 
genetic risk variants and their pathways and environmental triggers which all together could 
contribute to ASD. 
7TIIVISTELMÄ
Autismikirjon häiriöt ovat neuropsykiatrisia sairauksia, joille tunnusomaista ovat vaikeudet 
sosiaalisessa vuorovaikutuksessa ja kommunikaatiossa sekä elämää hallitsevat rutiinit ja 
rituaalit. Perintötekijöillä on havaittu olevan osuutta autismikirjon sairauksien synnyssä, 
mutta periytymismalli on monimutkainen ja luultavasti useiden geenimuutosten 
yhteisvaikutusten aiheuttama. Todennäköisesti myös ympäristötekijät yhdessä geneettisten 
riskitekijöiden kanssa kasvattavat riskiä autismin puhkeamiseen. 
Tämän tutkimuksen tarkoitus oli tunnistaa autismikirjon sairauksille altistavia 
geenimuutoksia suomalaisista potilaista ja kontrolleista koostuvissa aineistoissa. Aloitimme 
tutkimuksen hienokartoittamalla jo aiemmissa suomalaisissa tutkimuksissa autismikirjon 
häiriöihin kytkeytyvää kromosomialuetta Xq11.1-q21.33. Aineistona oli 99 autismikirjoon 
kuuluvaa perhettä. Paras kytkentäluku (LOD score) havaittiin markkerilla DXS1225 alueella 
Xq21.1 (NPLall=3.43). Alueelta sekveksointiin 5 autismin kandidaattigeeniä, mutta tautia 
aiheuttavia mutaatioita ei havaittu tutkituissa perheissä. Osatyössä IV havaitsimme kuitenkin 
vahvan assosiaation lähellä parasta kytkentäaluetta keskushermoston toimintaan liittyvässä 
protokadheriini-geenissä PCDH11X kromosomialueella Xq21. Kytkentäalueella on useita 
autismin ehdokasgeenejä, joten koko alueen sekvensointi olisi tarpeellista. 
Autismikirjon häiriöissä ja pakko-oireisessa häiriössä on havaittu glutamaatti 
aineenvaihdunnan poikkeavuuksia. Osatyössä II analysoimme yleisiä polymorfioita (SNPs) 
glutamaatti-transportteri geenissä SLC1A1 kromosomialueella 9p24, joiden on aiemmissa 
tutkimuksissa havaittu liittyvän pakko-oireiseen häiriöön. Aineistona oli 175 autismikirjoon 
kuuluvaa henkilöä ja 216 kontrollia. Tutkimme myös 4 SNPiä kromosomialueilta 9p24 
(rs1340513 ja rs722628) ja 11p12-13 (rs1358054 ja 1039205), joiden on aiemmin havaittu 
liittyvän autismiin laajassa kansainvälisessä tutkimuksessa (Autism Genome Project 2007). 
Tässä tutkimuksessa SNP rs1340513 assosioitui autismiin (P=0.007) metylointiin liittyvässä 
geenissä JMJD2C, joka sijaitsee geenin SLC1A1 lähellä. Lisäksi väitöskirjan osatyössä IV 
havaittiin assosiaatio eri autismimateriaalilla kromosomipaikkaan 9p24 geeneihin SLC1A1, 
JMJD2C ja PTPRD.
8Häiriöiden synapsien toiminnassa on epäilty liittyvän autismiin. Autisteilla on aiemmin 
havaittu haitallisia muutoksia synapsien syntyyn vaikuttavissa geeneissä NRXN1, NLGN3/4X
ja SHANK2/3. Osatyössä III analysoimme SHANK2 geenin mutaatioita 455 eurooppalaisessa 
autismiperheessä. Suomalaisia perheitä oli mukana 99. Tulokset osoittivat, että autismista 
kärsivillä oli selvästi verrokkeja enemmän sellaisia SHANK2-geenin haitallisia muutoksia, 
jotka olivat yhteydessä alentuneeseen synapsien tiheyteen. SHANK2-geenin deleetio ja 
autismissa aiemmin löydetty kromosomin 15q11-13 kopioluvun muutos löytyivät samoilta 
potilailta. Tulos tukee käsitystä että autismin puhkeamiseen vaaditaan useita haitallisia 
muutoksia perimässä. 
Neljännessä osatyössä teimme koko perimän laajuisen assosiaatioanalyysin uudessa 
suomalaisessa 83 autismiperheen ja 750 normaalin hengen kontrollimateriaalissa 
(Terveys2000-aineisto). Vahvimman assosiaation havaitsimme kromosomialueella 16p13.2 
geenissä RBFOX1, joka säätelee useiden autismiin liitettyjen geenien ilmentymistä ja 
silmukointia. Geenien välistä yhteistoimintaa havaittiin geenien NRXN1 ja UBA52, RBFOX1 ja 
SCN1A sekä DLG2 ja RBFOX3 välillä. Teimme myös promoottorianalyysin autismin 
kandidaattigeeneille ja havaitsimme mahdollisen transkription säätelyalueen geenissä 
AVPR1A, mikä voisi osittain selittää autismiin aiemmin liitetyn promoottorialueen 
polymorfian tässä geenissä. Lisäksi havaitsimme että sitoutumiskohta transkriptio faktorille 
EGR oli rikastunut autismin ehdokasgeeneissä verrokkigeeneihin verrattuna. Tutkimme tässä 
aineistossa myös kopioluvun muutoksia ja tunnistimme suuria (>400 kb) muutoksia 
kromosomialueilta 15q13.3, 16p11.2, 17q12 and 22q11. Kopioluvun muutoksia näillä alueilla 
on aiemmissa tutkimuksissa havaittu autismin lisäksi myös muissa neuropsykiatrisissa 
sairauksissa. Havaitsimme kopioluvun muutoksia myös autismiin aiemmin liitetyissä 
geeneissä DISC1, FOXG1, ASMT, PCDH11X ja PRODH.  
Tässä väitöskirjassa havaitut tulokset osoittavat että RBFOX1 geenin muutokset liittyvät 
autismiin suomalaisessa perhemateriaalissa ja vahvistavat käsitystä, että useat geneettiset 
muutokset ja niiden yhteisvaikutukset altistavat autismille. Lisätutkimukset ovat tarpeellisia 
selvittämään mitkä geneettisten variaatioiden yhdistelmät, yhdessä ympäristötekijöiden 
kanssa vaaditaan autismin puhkeamiseen. 
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ABBREVIATIONS
22q11DS 22q11 deletion syndrome 
aCGH   array comparative genomic hybridization 
ADHD   attention deficit-hyperactivity disorder 
ADI-R   Autism Diagnostic Interview - Revised 
ADOS    Autism Diagnostic Observation Schedule 
AGP   Autism Genome Project 
AGRE   Autism Genetic Resource Exchange  
APA American Psychiatric Association   
AS   Asperger syndrome 
ASD   autism spectrum disorders 
ASDI    Asperger Syndrome Diagnostic Interview 
ASSQ Asperger Syndrome Screening Questionnaire 
AVP     arginine vasopressin 
AVPR1A arginine vasopressin receptor 1A
bp   base pair 
CARS Childhood Autism Rating Scale 
CNV   copy number variation 
CY-BOCS Children´s Yale-Brown Obsessive-Compulsive Scale 
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th Edition 
EGR   early growth response 
EIBI   early intensive behavioral intervention 
GWAS   genome-wide association study 
HFA   high function autism 
HFAP   human alpha-fetoprotein  
ICD-10  International Classification of Diseases, 10th Revision 
ID intellectual disability 
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IMGSAC International Molecular Genetic Study of Autism Consortium 
JMJD2C jumonji domain containing 2C
kb kilobase 
LOD   logarithm of the odds  
LD   linkage disequilibrium 
MAF   minor allele frequency 
Mb   megabase
MDD   major depressive disorder 
NPL   non-parametric LOD 
OCD   obsessive compulsive disorder 
PCDH11X protocadherin 11 X-linked
PDD-NOS pervasive developmental disorder not otherwise specified 
PGC   Psychiatric Genomic Consortium 
PSD   postsynaptic density 
RBFOX1 RNA binding protein, fox-1 homolog (C. elegans) 1
SHANK2 SH3 and multiple ankyrin repeat domains 2
SLC1A1 solute carrier family 1, member 1 
SNP   single nucleotide polymorphism 
SRS Social Responsiveness Scale 
STR   short tandem repeat 
TDT   transmission disequilibrium test 
TF transcription factor 
WHO   World Health Organization 
XLID X-linked Intellectual disability 
Zmax   maximum LOD score 
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1 INTRODUCTION
Autism spectrum disorders (ASD) are characterized by abnormalities in communication and 
social interaction. Restricted repetitive and stereotyped behavior with unusual interests and 
activities is also typical. ASD affect an estimated 0.62 % of the population. ASD prevalence 
has been increasing, which might, in part, be a result of changing diagnostic criteria and 
more frequent reporting of ASD cases (Newschaffer et al. 2007).  ASDs are more common in 
men than in women, with an average male to female ratio of 4.3:1 (Fombonne 2005).
The word “autism” originates from the Greek word “autos”, which means “self”. It describes 
a situation in which individuals become absorbed in their own world and lose contact with 
other people. Eugen Bleuler was a Swiss psychiatrist who first used the term “autistic 
psychopathy” to describe the desire of schizophrenic patients to withdraw from public 
places (Bleuler 1916). The distinction between autism and schizophrenia remained 
controversial for a long time and autistic disorders were first introduced under the 
diagnostic criterion of childhood schizophrenia (DSM-II) (American Psychiatric Association 
1968). 
American psychiatrist Leo Kanner described 11 children, mostly boys with intellectual 
disability, repetitive and ritualistic interests and activities, delayed early language 
development and severe social isolation (Kanner 1943). Leo Kanner´s paper “Autistic 
Disturbances of Affective Contact” is the basis for the modern definition and today´s 
diagnostic criteria for infantile autism. Kanner also reported that an early cold relationship 
between the mother and the child might be the cause of autism. Bruno Bettelheim was an 
Austrian-American child psychologist and writer who popularized the "Refrigerator Mother" 
hypothesis of autism (Bettelheim 1967). Contrary to Kanner, he ignored that these same 
mothers had other children who were not autistic. The hypothesis was later rejected by 
scientists when the importance of the genetic background of autism became clear.  
A year after Kanner´s publication an Austrian paediatrician, Hans Asperger, described four 
boys with autistic psychopathy but normal intellectual abilities (Asperger 1944).  He called 
Introduction 
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them “little professors” who talked about their own interests but had difficulties with non-
verbal communication such as understanding other peoples´ facial expressions. He observed 
that the onset of this condition seemed to be later than in autism and it almost never 
became evident before three years of age. The combination of these problems were 
generally referred to as Asperger syndrome (AS) and knowledge of this condition began to 
expand after the English review by Lorna Wing (Wing 1981). 
ASDs have one of the highest heritability estimates of neuropsychiatric disorders and studies 
on the genetic component have been conducted since the 1980´s. The idea of genetic causes 
of autism has changed in the last few years. Autism has been suggested to be a polygenic 
disorder caused by multiple genetic risk factors, each with a weak effect. It has also been 
thought to be a group of disorders caused by heterogeneous genetic risk factors influencing 
common neuronal pathways (Bourgeron 2009, Toro et al. 2010) wherein only a single highly 
penetrant  mutation  could  cause  autism  in  a  limited  number  of  patients  (Betancur  2011).  
Girirajan  et  al.  (2010)  proposed  a  two-hit  model,  wherein  a  second  CNV  together  with  
16p12.1 microdeletion resulted in more severe clinical manifestation in developmental 
disorders. In this thesis, molecular genetic studies of mostly Finnish ASD cases are presented 
with several approaches including the study of candidate genes, genome-wide association 
(GWA) and copy number variants (CNVs). 
Review of the literature 
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2 REVIEWOFTHELITERATURE
2.1 AUTISMSPECTRUMDISORDERS
2.1.1 Clinical features and diagnostics 
Autism spectrum disorders (ASD) are a group of early onset developmental disabilities which 
all express difficulties in three core areas; communication, social skills and behavioral 
flexibility. The disorders express varying severity. According to the International 
Classification of Diseases (ICD-10) diagnostic criteria, ASDs include childhood autism, 
Asperger syndrome (AS), childhood disintegrative disorder, pervasive developmental 
disorder not otherwise specified (atypical autism) and Rett syndrome (World Health 
Organization 1993). 
Impairment of the communication exists across a broad spectrum and it affects both verbal 
and  nonverbal  communication  (Cashin  et  al.  2009).  In  most  children  with  ASD,  
communication skills are severely delayed. The majority of preschool-age children with 
childhood autism presents with little to no functional speech and must be taught to apply 
alternative forms of communication such as pictures, sign language, and speech generating 
devices. The use of intonation in speech and interpretation of other people´s use of it is also 
impaired. Non-verbal communication is restricted as well as understanding other people´s 
facial expressions.  
The impairment of social skills includes difficulties in interpreting communication and a lack 
of ability to form a theory about what other people are thinking or feeling (theory of mind) 
(Cashin et al. 2009). Impaired behavioral flexibility manifests as a restricted and repetitive 
range of interests and activities and, at times, in ritualistic manners. The restricted range of 
interests often arises as obsessions. These obsessions appear as a resource to mediate 
anxiety (Grandin & Scariano 1996). Compared to obsessive compulsive disorders (OCD) there 
is less fear of catastrophic consequences if the obsessive behaviors are not performed 
(Baron-Cohen & Wheelwright 1999). 
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Patterns of symptoms appear in childhood autism before the age of 3. It is characterised by 
delayed language development, unusual behavior, and social and communication difficulties 
as well as in some cases by delay in intellectual development. Only about 10 % of individuals 
with classical autism are able to live relatively independently; most require lifelong 
assistance (Howlin et al. 2004). Asperger syndrome (AS) exhibits no delay in language or 
cognitive development and has milder behavioral signs. AS is usually recognized later than 
classical autism, at preschool age (Khouzam et al. 2004). The detailed diagnostic criteria for 
childhood autism and Asperger syndrome are shown in Table 1.
Pervasive developmental disorder-not otherwise specified (PDD-NOS) also called “atypical 
autism” has fewer and milder symptoms compared to classical autism. Childhood 
disintegrative disorder has normal development for about 2 years, in terms of acquisition of 
communication skills, non-verbal behavior, and motor functioning and skills (such as toy 
play), and then substantial regression or loss of functioning appears (after 2 years). 
Rett syndrome is a rare neurodevelopmental disorder in females that is classified to ASD. It 
characterized by severe intellectual disability, hand-wringing stereotypes, hyperventilation, 
loss of purposive hand movements and autistic features. Rett syndrome is caused by 
mutations in the MECP2 (methyl-CpG binding protein 2) gene (Amir et al. 1999). In less 
than 5 % of the cases mutations in genes CDKL5 (cyclin-dependent kinase-like 5) or FOXG1
(forkhead box G1) are noticed to cause Rett syndrome (Ariani et al. 2008, Russo et al. 2009). 
15-47 % of children with ASD express autistic regression which occurs when a child appears 
to develop typically, but around the second year of life begin to lose the previously acquired 
speech and social skills, accompanied with onset of autistic features (Stefanatos et al. 2008). 
Autism with and without regression is a continuous spectrum of behaviors with some 
children expressing late losses and some early delays of skills (Ozonoff et al. 2008).    
Review of the literature 
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Table  1.  Diagnostic  criteria  for  childhood  autism  and  Asperger  syndrome  according  to  the  ICD-10  
classification (World Health Organization 1993).
Childhood autism F84.0
A Presence of abnormal or impaired development before the age of three years, in at least one out of 
the following areas: 
1. receptive or expressive language as used in social communication 
2. the development of selective social attachments or of reciprocal social interaction 
3. functional or symbolic play 
B Qualitative abnormalities in reciprocal social interaction, manifest in at least one of the following 
areas: 
1. failure adequately to use eye-to-eye gaze, facial expression, body posture and gesture to 
regulate social interaction 
2. failure to develop (in a manner appropriate to mental age, and despite ample opportunities) 
peer relationships that involve a mutual sharing of interests, activities and emotions 
3. A lack of socio-emotional reciprocity as shown by an impaired or deviant response to other 
people's emotions; or lack of modulation of behavior according to social context, or a weak 
integration of social, emotional and communicative behaviors. 
C Qualitative abnormalities in communication, manifest in at least two of the following areas:
1. a  delay  in,  or  total  lack  of  development  of  spoken language  that  is  not  accompanied  by  an  
attempt to compensate through the use of gesture or mime as alternative modes of 
communication (often preceded by a lack of communicative babbling) 
2. relative failure to initiate or sustain conversational interchange (at whatever level of 
language skills are present) in which there is reciprocal to and from responsiveness to 
communications of the other person
3. Stereotyped and repetitive language or idiosyncratic use of words or phrases
4. abnormalities in pitch, stress, rate, rhythm and intonation of speech
D Restricted repetitive, and stereotyped patterns of behavior, interests and activities, manifest in at 
least two of the following areas: 
1. an encompassing preoccupation with one or more stereotyped and restricted patterns of 
interest that are abnormal in content or focus; or one or more interests that are abnormal in 
their intensity and circumscribed nature although not abnormal in their content or focus. 
2. apparently compulsive adherence to specific, non-functional, routines or rituals 
3. stereotyped and repetitive motor mannerisms that involve either hand or finger flapping or 
twisting, or complex whole body movements 
4. preoccupations with part-objects or non-functional elements of play materials (such as their 
odour, the feel of their surface, or the noise or vibration that they generate) 
5. distress over changes in small non-functional, details of environment 
E The  clinical picture is not attributable to other varieties of pervasive developmental disorder; 
specific developmental disorder of receptive language (F80.2) with secondary socio-emotional 
problems; reactive attachment disorder (F94.1) or disinhibited attachment disorder (F94.2); mental 
retardation (F70-72) with some associated emotional or behavioral disorder; schizophrenia (F20) of 
unusually early onset; and Rett syndrome (F84.2). 
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The classification will soon (in year 2013) be altered by the fifth edition of the Diagnostic and 
Statistical Manual of Mental disorders (DSM-V). It will combine previously used subtypes, 
including  Asperger  syndrome,  and  the  disorders  will  be  treated  as  a  continuum  of  
phenotypes. It is also likely that Rett syndrome will be excluded from the group (Hebebrand
and Buitelaar 2011). Differences in the ICD–10 and DSM–IV definitions for the same disorder 
Asperger syndrome F84.5
A. A lack of any clinically significant general delay in spoken or receptive language or cognitive 
development. Diagnosis requires that single words should have developed by 2 years of age or 
earlier and that communicative phrases be used by 3 years of age or earlier. Self-help skills, 
adaptive behavior, and curiosity about the environment during the first 3 years should be at a level 
consistent with normal intellectual development. However, motor milestones may be somewhat 
delayed and motor clumsiness is usual (although not a necessary diagnostic feature). Isolated 
special skills, often related to abnormal preoccupations, are common, but are not required for the 
diagnosis. 
B. Qualitative abnormalities in reciprocal social interaction (criteria as for autism). Diagnosis requires 
demonstrable abnormalities in at least two out of the following four areas: 
1. Failure adequately to use eye-to-eye gaze, facial expression, body posture and gesture to 
regulate social interaction. 
2. Failure to develop (in a manner appropriate to mental age, and despite ample opportunities) 
peer relationships that involve a mutual sharing of interests, activities and emotions. 
3. Lack of socio-emotional reciprocity as shown by an impaired or deviant response to other 
people’s emotions, and/or lack of modulation of behavior according to social context, and/or 
a weak integration of social, emotional and communicative behaviors 
4. Lack of spontaneous seeking to share enjoyment, interests or achievements with other 
people (e.g. lack of showing, bringing or pointing out to other people objects of interest to 
the individual). 
C An unusually intense circumscribed interests, or restricted, repetitive, and stereotyped patterns of 
behavior, interests, and activities (criteria as for autism, however it would be less usual for these to 
include either motor mannerisms or preoccupations with part-objects or non-functional elements 
of play materials). Diagnosis requires demonstrable abnormalities in at least two out of the 
following four areas: 
1. An encompassing preoccupation with one or more stereotyped and restricted patterns of 
interests that is abnormal in context or focus; or one or more interests that are abnormal in 
their intensity and circumscribed nature though not in their content or focus. 
2. Apparently compulsive adherence to specific, non-functional routines or rituals. 
3. Stereotyped and repetitive motor mannerisms that involve either hand/finger flapping or 
twisting, or complex whole body movements. 
4. Preoccupation with part-objects or non-functional elements of play materials. 
D The disorder is not attributable to other varieties of pervasive developmental disorder; schizotypal 
disorder (F21); simple schizophrenia (F20.6); reactive and disinhibited attachment disorders of 
childhood (F94.1 and .2); obsessional personality disorder (F60.5); obsessive compulsive disorder 
(F42).
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have impeded international communication and research efforts. The American Psychiatric 
Association (APA) and the World Health Organization (WHO) aim to harmonize the 
upcoming DSM–V and ICD–11 classifications by minimizing or eliminating differences 
between these two classification systems (First 2009).
In addition to the core symptoms several other clinical findings, which are presented in Table 
2, are observed in a significant proportion of individuals with ASD. These impairments 
include sensory abnormalities, motor signs, sleep disturbance, gastrointestinal disturbance, 
epilepsy and comorbid psychiatric diagnosis (Geschwind 2009). 10 - 15 % of individuals with 
autistic features have a medical syndrome which is usually caused by a single gene disorder 
(Folstein  and  Rosen-Sheidley  2001).  The  most  common  of  these  are  Fragile-X  syndrome,  
tuberous sclerosis, neurofibromatosis, phenylketonuria, Rett syndrome and Angelman´s 
syndrome.  
The diagnosis of autism and intellectual disability is challenging because there is significant 
overlap between them. Intellectual disability is present in approximately 67 % of individuals 
with autism and 28 % of patients with intellectual disability have autistic features (Kaufman 
et al. 2010). Both in autism and in intellectual disability without autism the majority of the 
cases are males, suggesting a X-chromosomal effect. In fact, some molecular evidence has 
been obtained for a common genetic background for ASD and X-linked intellectual disability 
(XLID) (Laumonnier et al. 2004, Betancur 2011) (See chapter 2.4.3). 
Approximately 22 % of individuals with autism develop epilepsy later in life. Seizures begin 
after  the age of  10 in the majority  of  the patients.  In  some cases the seizures do not start  
until adulthood (Bolton et al. 2011). Epilepsy in autism is associated with intellectual 
disability, poorer verbal abilities and it is more common in females than males (Bolton et al. 
2011). Autistic individuals with epilepsy have an increased number of relatives with broader 
autism phenotype which indicate that familial liability to autism raises the risk for epilepsy in 
the proband (Bolton 2011). 
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Table 2. Domains of impairment in ASD. Adapted from (Geschwind 2009). 
Domain Autism Asperger PDD-NOS ASD
Social communication required required required
Language required - variable
Repetitive, restrictive behaviors required required variable
Sensory abnormalities >90 % 80 % variable 94 %
Developmental regressiona 15 % - 40 % ? ? 15 % - 40 %
Motor signsb 60 % -80 % 60 % 60 % 60 % -80 %
Gross motor delay 10 % ? ? 5 % -10 %
Sleep disturbance 55 % 5 % -10 % 40 % 50 %
Gastrointestinal disturbancec 45 % 4 % 50 % 4 % - 50 %
Epilepsyd 10 % -60 % 0 % - 5 % 5 % -40 % 6 % -60 %
Comorbid psychiatric diagnosise 70 % 60 % > 25 % 25 % -70 %
aLoss of function in either or both the language or social skills domain. 
bMotor signs include hypotonia, gait problems, toe walking, and apraxia. 
cSix months or more of diarrhea, constipation, reflux, or bloating. 
dThe range of epilepsy estimates reflects the presence of other comorbid features, such as concurrent 
intellectual disability or intellectual disability and cerebral palsy, which significantly increase epilepsy risk 
(25 %–30 % and 60 %, respectively). 
eMood disorders, conduct disorders, aggression, and attention deficit/hyperactivity disorder (ADHD). 
ADHD symptoms are observed in 25 % of children with ASD. 
ASDs often show obsessive repetitive symptoms that are characteristic to obsessive-
compulsive disorders. OCD (MIM 164230) belongs to the anxiety disorders and is 
characterized by intrusive senseless thoughts and impulses (obsessions) and repetitive 
intentional behaviors (compulsions). Individuals with ASD may be more susceptible to high 
anxiety because of their unique social, behavioral, communicative and sensory difficulties 
(Bellini 2006). Studies which used Children´s Yale-Brown Obsessive-Compulsive Scale (CY-
BOCS; Scahill et al. 1997) have observed that large subgroups of children with ASD engage in 
significant obsession and compulsions (Scahill et al. 2006, Zandt et al. 2007). 37 per cent of 
people diagnosed with ASD have comorbid obsessive compulsive disorder (Leyfer et al. 
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2006). There is a difference in obsessive compulsive symptoms between ASD and OCD. In 
ASD repetitive thoughts about a specific interest produce largely positive, affective emotions 
while OCD related obsessions are unpleasant and they are performed to reduce perceived 
threat (Spiker et al. 2012).  
Leyfer et al. (2006) reported that the prevalence rates for other comorbid psychiatric 
disorders  in  children  with  autism  are  44  %  for  specific  phobias,  31  %  for  ADHD,  24  %  for  
major depression and less than 2 % for bipolar disorder. None of the patients in that study 
met the diagnostic criteria for schizophrenia. Over 10 % of children with autism have a 
phobia of loud noises. Leyfer et al. (2006) emphasized that it is challenging to determine if a 
child´s difficulties are due to autism-related manifestations or comorbid psychiatric 
disorders.  
A Finnish study reported co-morbid psychiatric disorders in an Asperger/High functioning 
(HFA) autism sample set. They observed common (prevalence 74 %) and often multiple 
comorbid psychiatric disorders in AS/HFA; behavioral disorders were shown in 44 %, anxiety 
disorders in 42 % and tic disorders in 26 %. Major depressive disorder (MDD) and anxiety 
disorders as comorbid conditions indicated significantly lower levels of functioning (Mattila 
et al. 2010).  
Several studies have indicated a strong association between familial mood and anxiety 
disorders,  and  autism  (Piven  et  al.  1991,  Smalley  et  al.  1995,  DeLong  2004,  Cohen  and  
Tsiouris 2006). Cohen and Tsiouris (2006) observed that 36% of mothers and 17% of fathers 
of an autistic child had a lifetime history of a major mood disorder. All of the mothers with 
recurrent MDD or Bipolar Disorder had a first episode prior to the birth of their autistic child. 
This study hypothesized that shared risk alleles between autism and depression genes are 
accompanied by epistatic interactions among these genes that, in turn, modify the 
expression of each disorder. Depending upon the number and type of these risk alleles 
individuals are likely to have a specific autism or depression phenotype (Figure 1) (Cohen 
and Tsiouris 2006).  
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Figure 1.  This figure presents a Venn diagram of the hypothesized overlap of risk alleles 
(DEP/AUT  alleles)  that  are  common  to  both  autism  and  recurrent  mood  disorders.  The  
dashed arrows emerging from the DEP/AUT overlap represent this modifier gene effect. The 
shaded regions represent DEP/AUT modified sub-groups of autism and depression. 
Reprinted  with  permission.  Cohen  and  Tsiouris,  J.  Autism  Dev.  Disord.  2006.  
ABBREVIATIONS: DEP=depression, AUT=autism. 
Concerning anatomical differences to normal children, autism often involves early brain and 
head overgrowth. Abnormal brain and head overgrowth begins at 9-18 months of age, often 
concurrently  or  soon  after  emergence  of  clinical  signs  of  autism  (Courchesne  et  al.  2011).  
Overgrowth and neural dysfunction are evident in multiple brain regions that are involved in 
higher-order social, emotional, communication, and cognitive development (Courchesne et 
al. 2011). Figure 2 presents the parts of the brain which are affected by autism. 
Male children with autism have on average 67 % more prefrontal neurons than those in the 
control group. The autistic group also has greater than average brain weight. Pathological 
increase in neuron numbers may be a key contributor to brain overgrowth in autism. Genes 
located within copy number variation regions in autism may cause abnormal proliferation of 
neuronal cells during development (Courchesne et al. 2011). Apoptotic mechanisms during 
the third trimester and early postnatal life normally remove subplate neurons, which 
comprise about half the neurons produced in the second trimester and are present only 
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during  cortical  development  (Kanold  2009).  A  failure  of  that  early  developmental  process  
could also create a pathological excess of cortical neurons (Courchesne et al. 2011). 
Figure 2. Parts of the brain affected by autism 
(http://www.autisminformationservice.com/specialreport.html).
2.1.2 Prevalence
The initial assessment for the rate of childhood autism was 4 in 10000 children (Wing et al. 
1976).  Over  time  diagnostic  criteria  have  embraced  a  broader  phenotype  of  ASD  and  
estimates for ASD prevalence have increased from 1/1000 (Bryson et al. 1988) to the current 
1/150-1/200 for ASD and 1/500 for the narrow diagnosis of strict autism (Geschwind 2009). 
In a Finnish epidemiological study the prevalence of ASD was 8.4 in 1000 and that of autism 
was  4.1  in  1000  (Mattila  et  al.  2011).  A  recent  review  of  global  prevalence  reported  the  
median prevalence of ASD to be 6.2/1000 (Elsabbagh et al. 2012). There were no significant 
differences between populations. The evidence reviewed did not support a strong impact of 
ethnic, cultural or socioeconomic factors. However, rates from low- and middle-income 
countries are mainly lacking (Elsabbagh et al. 2012). Several factors influencing this rise of 
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prevalence have been proposed including the broadening of diagnostic criteria, better 
service availability and awareness of ASD in both the lay and professional public. All ASDs are 
generally more common in males than in females (ratio ~4:1). In high-functioning children 
with childhood autism, the male-to-female ratio can be as high as 8:1 (Fombonne 2005).  
2.1.3 Concordanceratesandrecurrencerisks
ASDs have the highest heritability compared to other neuropsychiatric disorders. In earlier 
studies monozygotic twins showed significantly higher concordance rates (36–95 %) for 
autism than did dizygotic twins (0–23 %), which confirmed the strong genetic component of 
autism (Folstein & Rutter 1977a, Folstein & Rutter 1977b, Steffenburg et al. 1989, Bailey et 
al. 1995). A recent twin study with a larger study sample estimated slightly lower 
concordance rates, 58 % in monozygotic pairs and 21 % for dizygotic pairs in males for strict 
autism. For female twins the concordance rate was 60 % for monozygotic pairs and 27 % for 
dizygotic pairs. For ASD, the concordance rate was 77 % for monozygotic pairs and 31 % for 
dizygotic pairs in males. For females these rates were 50 % for monozygotic pairs and 36 % 
for  dizygotic  pairs.  The  study  proposed  that  environmental  factors  explain  55  %  of  the  
liability to autism (Hallmayer et al. 2011). 
Earlier  studies  estimated  that  the  sibling  recurrence  risk  for  ASD  is  3-10  %  (Chakrabarti  &  
Fombonne 2001, Icasiano et al. 2004, Lauritsen et al. 2005). A recent study with large sample 
and prospective longitudinal design reported that even 18.7 % of infants with at least one 
older  sibling  with  ASD  developed  the  disorder  (Ozonoff  et  al.  2011).  If  there  are  2  autistic  
children in the family the recurrence risk for the third child is 25 %. The risk of having one or 
more features of ASD is 30 % in adult siblings (Folstein and Rosen-Sheidley 2001). Detailed 
genetic findings in ASD are reported in Chapter 2.4. 
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2.1.4 Environmentalfactors
Environmental factors may increase the risk for autism (Newschaffer et al. 2002, Hallmayer 
et al. 2011). A comprehensive meta-analysis examined over 60 prenatal and neonatal risk 
factors for autism (Gardener et al. 2011). Factors associated with autism risk were abnormal 
presentation, fetal stress, umbilical-cord complications, birth injury or trauma, multiple 
birth, maternal hemorrhage, summer birth, low birth weight, small gestational age, low 5-
minute Apgar score, feeding difficulties, congenital malformation, meconium aspiration, 
neonatal anemia, ABO or Rh-incompatibility and hyperbilirubinemia. Factors not associated 
in autism risk included assisted vaginal delivery, anesthesia, post-term birth, high birth 
weight and head circumference (Gardener et al. 2011).  
A recent genome-wide sequencing study revealed that paternal age is associated with an 
increasing rate of de novo mutations (Kong et al. 2012). These mutations increase the risk for 
ASD and schizophrenia,  thus advanced paternal  age is  a  risk  factor  (Kong et  al.  2012).  Pre-
conceptual exposure to environmental mutagens also causes de novo mutations. Mercury, 
cadmium, nickel, trichloroethylene and vinyl chloride are suggested mutagens with 
increased risk for autism (Kinney et al. 2010). A recent study reported that exposure to 
traffic-related air pollution during gestation and the first year of life is associated with autism 
(Volk et al. 2013). 
It has been noticed that autism prevalence is higher in towns with a prospering IT industry, 
like  Eindhoven  and  Silicon  Valley,  than  in  other  towns  of  similar  size  (Buchen  2011,  
Roelfsema et al. 2012). Baron-Cohen (2012) reported that scientists and engineers have an 
increased risk of having a child with autism. His theory suggests that mating of people with 
technical minds passes down linked groups of genes that confer useful cognitive talent, but 
also increase the child´s chances of developing autism. These genetic variants underlying 
autism may persist because they are co-inherited with variants underlying certain cognitive 
talents typical to both autism and the technical mind (Baron-Cohen 2012). Other factors, like 
higher  education  and  the  older  age  of  parents  could  also  explain  the  high  prevalence  of  
autism in these IT centers (Buchen 2011). 
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Inflammations are a possible trigger to autism. Congenital cytomegalovirus infection and 
rubella have been reported to be associated in autism (King 2011). On the other hand, the 
postulated risk of the MMR (measles, mumps and rubella) vaccinate and vaccines containing 
the preservative thiomersal to increase autism has been disproven by many studies 
(Farrington et al. 2001, Parker et al. 2004, Fombonne et al. 2006, Richler et al. 2006).  
Maternal factors in pregnancy linked to increased autism risk include valproic acid, 
thalidomide, alcohol, depression, schizophrenia, OCD, autoimmune disease, stress, allergic 
reaction, and hypothyroidism (King 2011). All of these factors may initiate the expression of 
genes which are sensitive to retinoid acid and/or estradiol, whether by directly increasing 
(promotion) or reducing the production of human alpha-fetoprotein (HFAP) (King et al. 
2011). Impaired HFAP level has a significant effect on the foetal brain. 
Other environmental factors which are associated with increased risk for autism include 
residence in regions that are urbanized, located in higher latitudes or experience high levels 
of precipitation. These are all associated with decreased sun exposure and increased risk for 
vitamin  D  deficiency  (Kinney  et  al.  2010).  Prenatal  lack  of  vitamin  D  increases  the  risk  of  
autism (Eyles et al. 2012). Respectively, children with ASD have been reported to have 
significantly  lower  levels  of  D  vitamin  in  their  plasma  than  controls  (Eyles  et  al.  2012).  D  
vitamin is synthesized in the skin triggered by sunlight and plays an important role in 
repairing DNA damage and protecting against oxidative stress, which is a key cause of DNA 
damage. Vitamin D deficiency contributes to higher mutation rates and impaired repair of 
DNA (Kinney et al. 2010). Skin pigmentation is also known to directly decrease the actinic 
production of vitamin D3 (Abrams 2002). Accordingly ASD prevalence increases in infants 
from migrant mothers with dark skin compared to offspring from lighter skinned migrants 
(Dealberto 2011). 
A higher prevalence of autism has been reported in children with conception in November in 
California (Mazumdar et al. 2012).  The reason for this was unclear but might be caused by 
seasonal flu, which in California generally peaks in two weeks of January. A similar 
occurrence in schizophrenia was associated with exposure to influenza during gestation 
(Mednick  et  al.  1994).  Mazumdar  and  colleagues  (2012)  reported  that  with  children  who  
were conceived in November in California, the second trimester coincided with the pollen 
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season. This could be explained by maternal asthma in the second trimester which is 
associated with an increased risk of autism. Another study reviewed more than 6.5 million 
births in California and reported that children conceived in winter are more likely to develop 
autism than those conceived in other months of the year (Zerbo et al. 2011). Environmental 
factors have been proposed to increase the prevalence of ASD 10-fold over the past 4 
decades. The reason for this increased prevalence rate of ASD may also be due to broader 
diagnostic criteria and more frequent reporting of ASD (Massing-Courtney et al. 2013). 
2.1.5 Treatment
Longitudinal studies indicate that the long-term prognosis of children diagnosed with autism 
is poor, with most of them not obtaining independent status (Geschwind 2009). At present, 
there are no curative or psychopharmacological therapies to effectively treat all symptoms 
of  the  disorder.  45  %  of  children  with  ASD  are  treated  with  psychotropic  medication.  
Currently only risperidone is FDA-approved for the treatment of autism (Geschwind 2009). 
Risperidone is a medicine which is used as an asymptomatic treatment for irritability.  
Early intensive behavioral intervention (EIBI), a treatment based on the principles of applied 
behavior analysis delivered for multiple years is one of the more well-established treatments 
for  ASD  (Reichow  et  al.  2012).  It  aims  to  lessen  the  impact  of  symptoms  in  ASD  like  
behavioral challenges and cognitive difficulties. The method breaks behaviors down into 
subcategories and teaches each specific subcategory through repetition, prompts and 
positive reinforcement. Several publications and meta-analyses indicate that EIBI may 
improve the quality of life and level of functioning for children with ASD (Howlin et al. 2009). 
However it does not produce significant changes in all areas of a child’s functioning and it is 
not effective for all children with ASD (Howlin et al. 2009).  
The need for functional medication is crucial. Also, the identification of genetic and other 
biomarkers for specific subtypes and their relation to treatment response constitute critical 
areas of research. It is also essential to gather more efficient pharmacologic and cognitive-
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behavioral therapies and a better notion of which therapy is most appropriate for which 
child.  
2.2 STRUCTUREOFTHEHUMANGENOME
The human genome is stored within the 23 chromosome pairs of the cell nucleus and the 
mitochondrion. Chromosome pairs comprise 22 pairs of autosomes and one pair of sex 
chromosomes (XX in females and XY in males). The total length of the genome (22 
autosomal chromosomes and the X chromosome) is 3615 cM (Kong et al. 2002).  
The international Human Genome Sequencing Consortium (Lander et al. 2001) and a 
company, Celera Genomics (Venter et al. 2001), produced the first complete sequences of 
the human genomes. These sequences covered about 90 % in 2001 and were later refined to 
99 % (International Human Genome Sequencing Consortium 2004). Since then the 
International Hapmap Project Consortium 2010, the 1000 Genomes Project Consortium 
2010 and many other studies have updated and complemented these studies (Lander 2011). 
The haploid human genome contains approximately 20,500 protein-coding genes (Clamp et 
al. 2007). Protein-coding sequences account for only a very small fraction of the genome 
(approximately 1.5 %), and the rest is associated with regulatory DNA sequences, introns, 
non-coding RNA molecules and sequences with indeterminate functions (Lander 2011). 
The sequences of any two human beings are about 99.9 % identical (Lander 2011). The 
human genome consists of just over three billion nucleotides and 0.1 percent of difference 
represents altogether three million variants between any pair of individuals. The vast 
majority of these variants have no functional significance. Sequence variations in the human 
genome include single nucleotide polymorphisms (SNPs), microsatellites and structural 
variations. The variations can be used as genetic markers to study differences between 
individuals and populations. On average there are 60 new mutations in every individual, 
compared  to  his/her  parents  (Conrad  et  al.  2011).  Even  monozygotic  twins  have  genetic  
differences due to mutations occurring during development, e.g. with differences in copy 
number variation profiles (Bruder et al. 2008).  
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It is estimated that a total of 10 to 30 million SNPs exist in the human population of which at 
least 1 % are functional. About 9 to 10 million are common SNPs with minor allele frequency 
(MAF) above 0.05 (International HapMap Consortium et al. 2007). The density of common 
SNPs is roughly about one per 300 bases and it varies along the genome. The mutation rate 
of the SNP is low, approximately 1.0 to 2.5 x 10-8 mutations per nucleotide per generation 
(Nachman  &  Crowell  2000,  1000  Genomes  Project  Consortium  2010).  SNPs  are  useful  
markers for association studies because most SNPs have likely arisen in a single mutation 
event in the past. 
Mechanisms behind genome variations are mutations and recombination. Mutations can be 
classified as spontaneous or induced mutations. Spontaneous mutations are caused by 
internal factors such as occasional random errors in DNA replication during cell division. 
Induced mutations are a result of external factors such as mutagenic radiation or chemicals.  
Based on the effect on structure mutations are classified as point mutations, insertions or 
deletions. They can also be classified as loss-of-function, gain-of-function or neutral 
mutations based on the effect they have on gene function. Genetic recombination breaks 
and  rejoins  DNA  strands  to  form  new  molecules  of  DNA  encoding  a  novel  set  of  genetic  
information. Recombination can occur between similar molecules of DNA, as in homologous 
recombination, usually occurring during mitosis. It can also occur between dissimilar 
molecules, as in non-homologous end joining in meiosis which creates novel combinations of 
the parental genomes which are then transmitted to the offspring. 
Microsatellites are also known as short tandem repeats (STRs) and are repeated sequences 
of 2-6 base pairs of DNA which are flanked by unique sequences on both sides. The number 
of repeats can vary between individuals. The human genome contains 150,000 
microsatellites. The mutation rate is much higher compared to SNPs, in the range of  
1.5 x 10-3 per locus per generation (Butler 2006).  Microsatellites are highly polymorphic 
which have made them a useful tool in forensics and gene mapping.  
Copy-number variations (CNVs) are alterations that result in an abnormal number of copies 
of one or more sections of DNA. CNVs correspond to relatively large regions of the genome 
that have been deleted or duplicated in certain chromosomes (Figure 3). Locus specific 
mutation rates for genomic rearrangement range between 10-4 and 10-5, and thus are more 
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frequent than point mutations (Lupski 2007). To date, 11,700 CNVs overlapping over 1000 
genes have been revealed (Redon et al. 2006, Conrad et al. 2006). 
CNVs account for roughly 13 % of human genomic DNA and each variation ranges from 
about  one  kilobase  (1000  nucleotide  bases)  to  several  megabases  in  size  (Stankiewicz  &  
Lupski 2010).  It is estimated that approximately 0.4 % of the genomes of unrelated people 
differ because of copy number variations (Kidd et al. 2008).      
Figure 3. Forms of genomic copy number variation. Reprinted with permission. Lee and 
Scherer, Expert Rev. Mol. Med. 2010. 
CNVs can be inherited or de novo. Large de novo CNVs are likely to be more often causative 
for diseases, especially if dosage-sensitive genes or regulatory sequences are affected by the 
genomic rearrangement (Stankiewicz & Lupski 2010). Mechanisms for the formation of copy 
number variations are non-allelic homologous recombination, non-homologous end joining 
and replication-error mechanisms (Stankiewicz & Lupski 2010). 
CNVs have been observed to be enriched in genes encoding secreted, olfactory, and 
immunity associated proteins. The overrepresentation of immunity and chemo-sensation 
genes in human CNVs could imply that they might have been selectively favored in recent 
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evolution in fighting infection and sensing our environment (Nguyen et al. 2006). Rare, large, 
often de novo CNVs have been linked to varying phenotypes including autism, 
developmental disorders and schizophrenia (de Vries et al. 2005, Sebat et al. 2007, 
Stefansson et al. 2008). 
2.3 GENEMAPPINGSTRATEGIES
In  this  chapter  an  overview  of  the  most  essential  methods  is  given,  with  emphasis  on  the  
methods used in this thesis. The purpose of genetic mapping is to identify a genetic variant 
which  influences  the  phenotype  of  interest.  The  most  commonly  used  markers  are  
microsatellites and SNPs. Microsatellites are informative due to their high polymorphism 
content. SNPs compensate for their higher density in the genome which allows numbers of 
them to be genotyped.  
Figure 4 illustrates the relationship between the frequency of genetic variants and disease 
susceptibility. Higher penetrance, lower frequency variants that are not detected by current 
GWA approaches are amenable to new high-throughput sequencing efforts and might 
provide valuable information for genetics of complex disorders (McCarthy et al. 2008). 
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Figure 4. Genetic variants and disease susceptibility. Reprinted with permission. McCarthy et 
al. Nat.Rev.Genet. 2008. 
2.3.1 Linkageanalysis
Linkage is the tendency for a causal variant and a genetic marker to be inherited together 
because of their location near one another on the same chromosome. The aim of linkage 
analysis is to reveal those chromosomal loci, which harbor genetic variant(s) predisposing to 
a certain phenotype. For this purpose, the genome is covered by genotyping a number of 
genetic markers, and analyzed for co-segregation of the phenotype and the markers. 
Parametric linkage analysis is suitable for phenotypes where the inheritance pattern is 
known, whereas nonparametric linkage analysis is applicable also for phenotypes with less 
clear patterns of inheritance. Parametric linkage analysis follows co-segregation of two 
genetic factors, the marker and the phenotype, at specific loci in pedigrees using the 
frequency of meiotic recombination as an estimate of genetic distance. Parametric linkage 
analysis produces a logarithm of the odds (LOD) score that statistically estimates whether 
the marker and postulated disease loci are likely to lie near each other on a chromosome. A 
LOD score of 3 or more is generally taken to indicate that the two loci are linked. 
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Nonparametric linkage analysis detects markers in which affected relatives share alleles 
more often than expected by chance. Linkage analysis benefits from large pedigrees because 
they provide information from many meioses. On the other hand, the accuracy of the 
method is limited due to the requirement of informative meiosis: it can only identify rather 
large genomic regions, which is why other methods are warranted to narrow down the 
region of interest.
2.3.2 Associationanalyses
Association analyses test whether single locus allele frequencies differ between cases and 
controls. Individuals who share a disease mutation through common descent are likely to 
also share a haplotype of alleles surrounding the mutation. Typically, one does not find the 
direct causal allele but more probably markers in linkage disequilibrium (LD) with it. Thus, LD 
is a term for non-random association of alleles at two or more loci. In the genome LD exist as 
haplotype blocks in varying length and consist of regions with low recombination rates. 
Especially with complex traits, genome-wide association studies (GWAS) are an effective tool 
to detect disease associated genes.  In GWAS, allele frequencies of hundreds of thousands of 
SNPs are compared between cases and controls. Furthermore, the number of study subjects 
tends to be high: even in the order of thousands. Though rather labor-intensive and costly, 
the  total  number  of  GWA  studies  published  to  date  is  approaching  1459  
(www.genome.gov/GWAStudies, accessed 11/12/2012).  
One problem with the case-control design is that genotype and haplotype frequencies vary 
between ethnic or geographic populations. If the case and control populations are not well 
matched for ethnicity or geographic origin then false positive association can occur because 
of these differences. Family-based association designs aim to avoid this issue by using the 
parents as “pseudo”- controls for the case. With family-based association, the most 
commonly used test is the transmission disequilibrium test (TDT). TDT measures association 
by transmission of alleles from parents to affected offspring. If an allele increases the risk of 
having a disease then that allele is expected to be transmitted from parent to affected 
offspring more often than other alleles. 
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2.3.3 ScanningmethodologiesforCNV
Numerous array-based platforms for CNV detection exist utilizing the technologies based on 
Array -Comparative Genomic Hybridization (aCGH) and SNP genotyping or both (Haraksingh 
et al. 2011). In this thesis we utilized Illumina the SNP array in both the GWA study and CNV 
detection. 
Array comparative genomic hybridization (aCGH) is a molecular method for the discovery of 
genomic  imbalances  (Figure  5).  To  identify  copy  number  gain  or  loss  from  DNA,  samples  
from 2 different individuals, usually from the test and a control individual, are labeled with 
distinctive  fluorophores.  The  samples  are  simultaneously  hybridized  with  a  set  of  
hybridization targets, typically long oligonucleotides, in situ to  the  same  well  in  the  array  
platform. After this, the platform is scanned and the scan gives the intensity ratio of the two 
fluorescence signals that represent the average copy number ratio between the two 
genomic DNA samples. The fluorescence signals are analyzed by computer software, and a 
gain or loss of fluorescence signal intensity from the test DNA implies a gain or loss of test 
DNA copy numbers (Choy et al. 2010).  
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Figure 5. Diagram of the microarray-based comparative genomic hybridization (aCGH) 
process (Theisen 2008). 
High-throughput array technologies for identifying SNPs can also be used to identify CNVs. 
The SNP array consists of probes for the detection of both SNPs and CNVs. First, the sample 
DNA is labeled with fluorescent dye and then the sample is hybridized with a single stranded 
genetic probe of interest. In the SNP genotyping array only one sample is hybridized per 
microarray, therefore in this method control DNA is not needed. Instead of comparing 
intensities  from  two  samples,  the  log2 ratios are generated by clustering the intensities 
measured at each probe across many samples (Alkan et al. 2011).  The intensities from each 
microarray spot of the platform are generated by the difference in hybridization between 
the sample DNA and probe. The hybridization differs because of the presence or absence of 
different SNP’s in the sample DNA. Statistical algorithms have been developed to analyze the 
data of the intensity ratios, with which the CNV statuses of the tested individual can be 
determined. 
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2.3.4 Sequencing-basedmethods
Traditional Sanger sequencing (Sanger and Coulson 1975) has typically been used for the 
mutation search in candidate genes identified through linkage or association analysis, or for 
genes of interest based on functional studies. The aim of the sequencing is to identify the 
actual risk variants present in cases but not in controls. Recent development of high-
throughput sequencing methods has enabled genome wide sequencing of large cohorts. 
Whole genome resequencing produces a massive amount of data, and needs to be followed 
by bioinformatic analyses to filter out risk variants from benign polymorphisms. With costs 
rapidly decreasing it is now possible to sequence exomes or entire genomes of individuals 
for the purpose of research.  
2.4 MOLECULARGENETICSTUDIESINASD
Many experimental methods have been used to identify ASD associated genes, including the 
earlier linkage analyses and candidate gene association or experimental studies in animal 
models as well as the more recent genome-wide association studies, genome-wide CNV 
studies and expression profiling. It is estimated that the genetic cause can be identified in up 
to 20 % of ASD cases (Vorstman & Ophoff 2013). The results of autism studies have been 
compiled in e.g. AutismKB (http://autismkb.cbi.pku.edu.cn/), which is an evidence-based 
knowledgebase of ASD genetics. In this chapter the major molecular genetic findings in ASD 
are presented. Figure 6 illustrates ASD related loci reported in linkage, GWA, CNV and 
candidate gene studies. 
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Figure 6. Replicated findings of linkage (red bars), Genome-wide association (yellow bars), 
copy number variation (green bars) and candidate gene (blue bars) studies. Reprinted with 
permission. Freitag et al. Eur. Child Adolesc. Psychiatry, 2010. 
2.4.1 Linkagestudies
The first genome-wide screen in autism was published in 1998 showing the highest linkage 
peak at chromosome 7q22-q31 (IMGSAC 1998).  Since that as many as 158 linkage regions 
have been reported to associate with ASD, comprising all the chromosomes (Xu et al. 2012). 
Replicated linkage in ASD, as detected by at least two independent studies has been 
obtained in regions 2q21–33, 3q25–27, 3p25, 4q32, 6q14–21, 7q22, 7q31–36, 11p12–13 and 
17q11–21 (Freitag et al. 2010). A meta-analysis confirmed the region 7q22–32, and reported 
suggestive evidence for linkage to 10p12–q11.1 and 17p11.2–q12 (Trikalinos et al. 2006). 
Several genome-wide linkage studies in ASD have been performed with limited concordance 
of linked loci, reflecting either numerous genes of weak effect and/or sample heterogeneity. 
The summary of the best replicated linkage results in ASD are shown in Table 3.   
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The largest linkage study today is by the Autism Genome Project Consortium (AGP) (Szatmari 
et al. 2007), which reported the linkage and CNVs from altogether 1181 families with at least 
2 affected individuals each. Chromosomal region 11p12-13 reached suggestive but not 
genome wide significance. This locus has not been implicated in previous linkage scans. 
Locus 9p24 also showed suggestive linkage. Both of these chromosomal regions contain 
glutamate transporter genes which are candidate genes in ASD. SLC1A1 (solute carrier family 
1, member 1) locates at 9p24 and SLC1A2 (solute carrier family 1, member 1) at 11p12-13. At 
11p12-13,  stratification  of  the  sample  set  into  families  with  only  male  cases  and  families  
with also female cases yielded more significant peaks in the female containing families. 
Based on the CNV analyses, further stratification of families was performed to decrease 
heterogeneity, and suggestive linkage evidence was observed also for 15q23–25.3, in 
addition to 11p12–p13. 
The lack of genome-wide significant linkage findings is probably due to the genetic 
heterogeneity of the studied samples. Genetic and diagnostic heterogeneity is an underlying 
problem specifically in international collaborations where hundreds of samples are collected 
from many different countries. To decrease genetic heterogeneity, study samples have been 
divided into endophenotypes. Endophenotype is a term which is used to parse behavioral 
symptoms into more stable phenotypes with a clear genetic connection. This approach, 
however, reduces the power of the analysis due to smaller sample size. Stratification studies 
using a clinical sub-phenotype include two Finnish studies concerned with Asperger 
pedigrees  only  (Ylisaukko-oja  et  al.  2004,  Rehnström  et  al.  2006).  Other  subgroups  in  ASD  
linkage studies comprise, for instance, sex (Szatmari et al. 2007), age at first word (Alarcon et 
al. 2002, Alarcon et al. 2005, Schellenberg et al 2006), obsessive compulsive behavior 
(Buxbaum et al. 2004) and social responsiveness (Duvall et al. 2007). 
The original Finnish genome-wide linkage study in autism revealed the strongest linkage in 
locus 3q25-27 (Auranen et al. 2002). Other putative linkage findings were observed at 1q21-
23 and Xq11.  Based on this first linkage study, fine mapping within the best loci were 
performed. Fine mapping confirmed linkage peaks at chromosomal regions 1q23 (Kilpinen et 
al. 2009) and at Xq13.1 (Ylisaukko-oja et al. 2005). In genome-wide studies with extended AS 
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families the most solid linkage finding was observed at 3p14-24 (Ylisaukko-oja et al. 2004, 
Rehnström et al. 2006). 
In many studies the same family material has been included to the linkage and association 
analyses  and  in  most  of  these  studies  linkage  peaks  did  not  overlap  with  the  association  
peak. This suggests that the linkage peaks contain rare, highly penetrant risk alleles while 
associated  alleles  detected  in  GWA  studies  are  common  variants  with  low  risk.  SNP  data  
used in association analyses should be utilized in linkage analyses by characterizing genome 
wide SNP data through homozygosity and haplotype sharing analysis within families.  
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Table 3. Summary of linkage peaks in autism spectrum disorders with support from 
independent studies. Listed are loci obtaining a logarithm of odds (LOD) score > 3 in at least 
one study, and a LOD > 2 in at least one additional study. Table adapted from Abrahams and 
Geschwind (2008). 
Locus Phenotype Cohort Best marker References
1q21-q23 ASD FIN D1S1653 Auranen et al. (2002)
AS FIN D1S848 Ylisaukko-oja et al. (2004)
2q24-q31 ASD IMGSAC D2S2188 IMGSAC (2001)
ASD US D2S364 Buxbaum et al. (2001)
3q25-27 ASD FIN D3S3037 Auranen et al. (2002)
ASD UTAH rs1402229 Coon et al. (2005)
5p13-p14 ASD AGP S1968011 Szatmari et al. (2007)
ASD AGRE D5S2494 Liu et al. (2001)
ASD AGRE D5S1473 Yonan et al. (2003)
7q22-q31 ASD IMGSAC D7S477 IMGSAC (1998)
ASD IMGSAC D7S477 IMGSAC (2001)
7q34-36 Age at first word AGRE D7S1824 and 
D7S3058 
Alarcon et al. (2002)
Age at first word AGRE D7S2426 Alarcon et al. (2005)
9q33—q34 Age at first word CPEA S9S164 Schellenberg et al. (2006)
ASD AGP rs536861 Szatmari et al. (2007)
11p12-13 ASD AGP rs1358054 Szatmari et al. (2007)
SRS score AGRE ATA34E08 Duvall et al. (2007)
17q11-21 ASD AGRE D17S1294 Stone et al. (2004)
ASD AGRE D17S2180 Cantor et al. (2005)
ASD AGRE D17S1800 Yonan et al. (2003)
ABBREVIATIONS: FIN=Finland, IMGSAC=International Molecular Genetic Study of Autism 
Consortium, AGRE=Autism Genetic Resource Exchange, CPEA=Collaborative Programs of 
Excellence in Autism Network at the National Institute of Health, AGP=Autism Genome 
Project, SRS=Social Responsiveness Scale. 
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2.4.2 Genome-wideassociationstudies
Four GWA studies to date (December 2012) have reached genome-wide significant 
associations with ASD. Wang and colleagues (2009) performed a GWA study for a cohort of 
780 families (3101 subjects) from the Autism Genetic Resource Exchange (AGRE) and a case-
control cohort of 1204 affected individuals and 6491 controls. The combined sample set 
consisted  of  more  than  10000  subjects  of  European  ancestry.  The  most  significant  SNP,  
rs4307059 on chromosome 5p14.1, reached a P-value of 2.1 x 10-10 with the combined 
dataset. This SNP locates between genes cadherin 9 (CDH9) and cadherin 10 (CDH10) which 
both encode neuronal cell adhesion molecules. A recent study identified functional 
noncoding RNA MSNP1AS (moesin pseudogene 1, antisense) which is transcribed within the 
linkage  peak  at  5p14.1  (Kerin  et  al.  2012).  It  is  94  %  identical  and  antisense  to  the  X  
chromosomal MSN gene that encodes the moesin protein which regulates neuronal 
architecture. Individuals with ASD who carry a T allele of SNP rs4307059 showed increased 
expression of MSNP1AS in postmortem samples of the temporal cortex. MSNP1AS
noncoding RNA binds to MSN and could regulate the level of moesin in human cell lines and 
thus contribute to ASD risk. 
Weiss and colleagues (2009) reported the results of a genome wide linkage and association 
scan of 1031 multiplex autism families with altogether 1553 affected individuals. They 
identified a suggestive association with ASD on chromosomes 6q27 and 20p13.  Genotyping 
of the top hits with additional families revealed significant association of autism with a SNP 
on chromosome 5p15 between SEMA5A (semaphoring 5A) and TAS2R1 (taste receptor type 
2 member 1) (P=2 x 10-7). Expression analyses with brain tissue samples of 20 cases and 10 
controls showed that expression of the SEMA5A gene was reduced in the brains of autistic 
patients. This study had partly overlapping samples with Wang et al. (2009) but both studies 
also included unique datasets.  In contrast to Wang et al. (2009), Weiss et al. (2009) did not 
detect a significant association of SNP rs4307059 and ASD on chromosome 5p14.1. 
The Autism Genome Project (AGP) performed a genome wide scan by genotyping 1 million 
SNPs in 1558 ASD families (Anney et al. 2010). The AGP consortium represents more than 50 
centers in North America and Europe. In this study SNP rs4141463 at the MACROD2 (MACRO 
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domain containing 2) gene on chromosome 20p12.1 reached genome wide association 
significance threshold P < 5 x  10-8 within strict diagnosis and European ancestry. After this 
first stage, the Autism Genome Project added 1301 ASD families at Stage 2 and performed a 
GWA study with altogether 2705 ASD families (Anney et al. 2012). The strongest association 
was now detected at SNP rs1718101 in European individuals with higher IQ (P=7.8 x 10-9). 
This SNP locates in the CNTNAP2 (contactin associated protein-like 2) gene on chromosome 
7q35. Association to the MACROD2 gene was not detected at Stage 2.  
The GWA studies described here did not replicate each other´s findings. Currently, common 
gene variants explain less than 5 % of the risk of ASD (Connolly et al. 2012). Obviously, the 
genetic complexity and heterogeneity of ASD individuals hampers GWA studies. Connolly 
and colleagues (2012) aimed to reduce this complexity by targeting to endophenotypes. This 
GWA study of 2165 ASD individuals examined the association between genomic loci and a 
specific endophenotype of ASD. Assessment tools were the ADI-R (Autism Diagnostic 
Interview-Revised), ADOS (Autism Diagnostic Observation Schedule) and SRS (Social 
Responsiveness Scale).  They identified a number of loci with significant associations. Genes 
showing association of specific endophenotypes were KCND2 (potassium voltage-gated 
channel, Shal-related subfamily, member 2) in overly serious facial expression, NOS2A (nitric 
oxide synthase 2, inducible) in loss of motor skills and NELL1 (nel-like 1 isoform 1 precursor) 
in faints, fits, or blackouts. The replication of this strategy is warranted to confirm the 
findings. 
The Psychiatric Genomics Consortium (PGC) which conducts meta-analyses of genome wide 
genetic data for psychiatric diseases detected genome-wide significant associations with 
schizophrenia for seven loci (Schizophrenia Psychiatric Genome wide Association Study 
(GWAS)  Consortium  2011)  in  a  very  large  material  (>20  000)  size.  The  PGC  is  also  
incorporating ASD samples and it is assumed that new genome-wide significant loci in ASD 
will be detected with large enough study material.    
Review of the literature 
44
2.4.3 Candidategenestudies
According to AutismKB, 434 genes related to autism have been detected (Xu et al. 2012). 
These genes are mapped to pathways including neuroactive ligand-receptor interaction, 
synapse transmission and axon guidance. Positional and functional evidence to identify 
autism candidate genes is gained from GWA studies, genome wide CNV studies, linkage 
analyses, low-scale genetic association studies, expression profiling, mouse models and 
other experimental studies. In addition, the results between studies vary, -mainly because of 
the differences in sample sizes, ethnic groups and phenotypes. Some studies include all ASD 
individuals while others focus on infantile autism only. This thesis focuses on the autism 
candidate genes SHANK2, SLC1A1, AVPR1A and also a few known genes underlying 
intellectual disability. These genes are reviewed in the following section. 
The genetic causes of ASD are diverse (Betancur 2011), but the main category of genes 
associated with the disorder is related to the development and function of neuronal circuits 
(Toro  et  al.  2011,  Gilman  et  al.  2011).  Rare  mutations  in  NLGN3 (neuroligin 3), NLGN4X
(neuroligin 4, X-linked) (Jamain et al. 2003), SHANK3 (SH3 and multiple ankyrin repeat 
domains 3) (Durand et al. 2007), SHANK2 (SH3 and multiple ankyrin repeat domains 2) 
(Berkel  et  al.  2010)  and  NRXN1 (neurexin  1)  (Ching  et  al.  2010)  have  revealed  pathways  
affecting  synaptic  functions  in  autism  (Figure  7).  These  proteins  play  a  crucial  role  in  the  
formation and stabilization of synapses (Südhof 2008), as well as in synaptic homeostasis (Yu 
and Goda 2009). SHANK2 and SHANK3 code for scaffolding proteins located in the 
postsynaptic density (PSD) of glutamatergic synapses. Deletions of SHANK3 on chromosome 
22q13 are one of the major genetic abnormalities in neurodevelopmental disorders (Cooper 
et al. 2011): mutations of SHANK3 have been identified in patients with ASD, intellectual 
disability (ID) and schizophrenia (Durand et al. 2007, Moessner et al. 2007, Gauthier et al. 
2010, Hamdan et al. 2011). Mutations of SHANK2 have also recently been reported in both 
ASD  and  ID  (Pinto  et  al.  2010,  Berkel  et  al.  2010).  Differences  in  the  clinical  outcome  of  
mutation carriers has been attributed to the presence of still uncharacterized additional 
genetic, epigenetic and/or environmental factors (Persico and Bourgeron 2006). Genetic 
epistasis between the NRXN-NLGN-SHANK pathway is suggested to have a significant role in 
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ASD.  Figure  7  illustrates  the  ASD  associated  genes  involved  in  neurodevelopment  and  
synaptic functions. 
Figure 7.  Proteins that are altered in function or amount in ASD. Reprinted with permission. 
Persico and Bourgeron, Trends Neurosci. 2006. 
The 9p24 locus is a common candidate for obsessive compulsive disorder and autism (Hanna 
et al. 2002, Willour et al. 2004, Szatmari et al. 2007).  This region contains the SLC1A1 gene 
which encodes a neuronal glutamate transporter EAAC1 (excitatory amino acid carrier 1). 
SLC1A1 is expressed in the cortex, striatum and thalamus. Neuroimaging studies have found 
that neurotransmitter concentrations are lower in the anterior cingulate and greater in the 
caudate in OCD patients compared to controls. Glutamatergic levels in the caudate decrease 
to control level following treatment with serotonin re-uptake inhibitors (Rosenberg et al. 
2000, Rosenberg et al. 2004). Several studies of OCD have detected a significant association 
at  single  nucleotide  polymorphisms  (SNPs)  covering  the  SLC1A1 gene region (Arnold et al. 
2006, Dickel et al. 2006, Stewart et al. 2007, Shugart et al. 2009, Wendland et al. 2009, 
Samuels et al. 2011). As stated in Chapter 2.1.1 ASD patients often manifest repetitive 
symptoms similar to OCD patients (Bodfish et al. 2000, Russell et al. 2005, Leyfer et al. 2006). 
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In OCD, an autistic subtype with social deficits has been suggested (Bejerot et al. 2001, 
Bejerot 2007). Recently, some evidence for the association of SLC1A1 in male patients with 
autism (Brune et al 2008) and anxiety in autism (Gadow et al. 2010) has been reported. 
The receptor coded by AVPR1A (arginine vasopressin receptor 1A) gene, V1aR, mediates the 
influences of the arginine vasopressin (AVP) hormone in the brain, which has a prominent 
role in higher cognitive functions, such as memory and learning (Fink et al. 2007). AVPR1A
mediates many social, emotional and behavioral traits, including pair bonding, parenting, 
sibling relationships, altruism (Donaldson and Young 2008) and musical aptitude (Ukkola et 
al.  2009,  Ukkola-Vuoti  et  al.  2011).  Therefore,  it  has  been  suggested  as  an  important  
candidate gene for ASD and a number of studies have observed the association with autism 
(Kim  et  al.  2002,  Wassink  et  al.  2004,  Yirmiya  et  al.  2006,  Yang  et  al.  2010a,  Yang  et  al.  
2010b, Tansey et al. 2011). Notably, practically all associations found with the AVPR1A gene
are located in the promoter region of the gene. In this thesis the promoter of the AVPR1A
gene was studied in detail. 
At  least  50  genes  identified  are  associated  with  syndromic  X-linked  ID  and  over  40  genes  
with non-syndromic X-linked ID (Betancur 2011). Several genes first reported in syndromic 
conditions were later detected in subjects with non-syndromic forms e.g. ARX (aristaless 
related homeobox), CASK (calcium/calmodulin-dependent serine protein kinase), JARID1C 
(jumonji, AT rich interactive domain 1C) and ATRX (alpha thalassemia/mental retardation 
syndrome X-linked) (Betancur 2011). Several distinct, individually rare genetic causes in ASD 
have been detected which resemble the genetic architecture of ID. In fact all known genetic 
variants  associated  with  ASD  are  also  causes  of  ID,  indicating  a  common  genetic  basis  for  
these two neurodevelopmental disorders (Betancur et al. 2011).  Many well recognized ID 
genes can also predispose to ASD, with or without ID. Genes found both in ID and autism are 
e.g. PTCHD1 (patched domain containing 1), JARID1C, GRIK2 (glutamate receptor, ionotropic, 
kainate 2), IL1RAPL1 (interleukin 1 receptor accessory protein-like 1), SHANK3 and NLGN4X
(Kaufman et al. 2010, Betancur 2011). Known X-linked genes associated with ID and/or ASD 
are presented in Figure 8. 
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Figure 8. Genes implicated in syndromic and/or non-syndromic forms of X-linked intellectual 
disability (XLID) and their localization on the X chromosome. Genes that have been reported 
to be mutated in ASD are highlighted in red. Genes that cause syndromic forms of XLID are 
shown on the left; those that can cause non-syndromic forms are on the right. The 
distinction between syndromic and non-syndromic genes is not precise, and for several 
genes on the right, mutations have been reported in families with syndromic as well as non-
syndromic XLID; the syndromic presentation is indicated in parentheses. Reprinted with 
permission. Betancur, Brain. Res. 2011. 
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The most common single gene disorder in ASD is Fragile X syndrome caused by mutation in 
the FMR1 (fragile X mental retardation 1) gene, which is present in about 2 % of ASD cases. 
Other monogenic disorders (mutated gene in brackets) described in ASD are Rett syndrome 
(MECP2, CDKL5, FOXG1),  tuberous  sclerosis  (TSC1, TSC2) and neurofibromatosis (NF1)
(Betancur 2011).   
2.4.4 StructuralvariationsandCNVs
Microscopically detectable chromosomal aberrations have been estimated to account for ~5 
%  of  ASD  cases  (Betancur  2011).  The  most  common  cytogenetic  abnormality  in  ASDs,  
accounting for approximately 1-3 % of cases is maternal duplication of the imprinted 15q11-
q13 region (Stankiewicz & Lupski 2010). This region overlaps with the deletion causing 
Angelman syndrome and Prader-Willi syndrome, both of which also have overlapping clinical 
symptoms with ASDs (Veltman et al. 2004, Bonati et al. 2007).  Other common cytogenetic 
abnormalities in ASD are deletions of 2q37, 7q22q31, 18q21q23, 22q13.3, and Xp22; 
duplications of 7q11.23 and 17p11.2 and aneuploidy of chromosome Y (Stankiewicz & Lupski 
2010). 
The first systematic study of submicroscopic chromosomal rearrangements in idiopathic ASD 
revealed an excess of de novo CNVs in individuals with autism (Sebat et al. 2007). The de 
novo CNVs were particularly enriched in families with only one affected individual. The 
overlap between identified CNVs was small; most CNVs were detected only in a single 
individual. The AGP linkage study was the first autism study where genome wide SNP data 
was assessed for variation in copy number of submicroscopic regions (Szatmari et al. 2007). 
Thereafter evidence for the role of CNVs in the multilayered etiology of ASD has been 
obtained from several studies (Marshall et al. 2008, Glessner et al. 2009, Pinto et al. 2010, 
van der Zwaag et al. 2010, Levy et al. 2011, Salyakina et al. 2011, Sanders et al. 2011). 
Recurrent microdeletions and microduplications in ASD have been identified on 
chromosome 16p11.2 (Kumar et al. 2008, Weiss et al. 2008). A known recurrent 
microdeletion at 22q11.2 has been associated with increased rates of ASD (Vorstman et al. 
2006). 
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The submicroscopic deletions and duplications may affect ASD risk genes and/or their 
regulatory elements that function in multiple cellular processes, like in neurodevelopmental 
pathways (Kakinuma & Sato 2008, Bourgeron 2009, Pinto et al. 2010, Sanders et al. 2011, 
Berkel et al 2012).  Added to this, CNVs overlapping with the ones observed in autism have 
been found in other neuropsychiatric disorders including schizophrenia, intellectual 
disability, attention deficit hyperactivity disorder and epilepsy syndromes suggesting a 
partially shared genetic background (Guilmatre et al. 2009, Betancur 2011, Cooper et al. 
2011, Elia et al. 2011, Glessner et. 2012). These CNVs have been discovered more often in 
patients  than  in  the  normal  control  population  (Marshall  et  al.  2008,  Glancy  et  al.  2009,  
Sanders et al. 2011).   
There is evidence that de novo copy number variants (CNV) contribute to autism risk in 5-15 
% of  cases in families  with one affected individual  (Sebat et  al.  2007,  Marshall  et  al.  2008,  
Glessner et al. 2009, Pinto et al. 2010, Levy et al. 2011, Sanders et al. 2011). Inherited CNVs 
are found in up to 50 % of ASD subjects for whom one of the presumable normal parents 
also has the CNV. These familiar CNVs may include candidate genes relevant to ASD when 
they are rare in the normal population (Li et al. 2012). Most of the reported CNVs in autism 
have been large (over 400kb) (Sebat 2007, Marshall 2008, Glessner 2009). The recent 
development of single nucleotide polymorphism platforms has improved the resolution and 
enabled researchers to detect smaller CNVs (Haraksingh et al. 2011).   
2.4.5 Exomesequencing
The recent development of sequencing technologies provides an effective tool to detect 
basically all variants in the human genome. Exome sequencing is a powerful tool to detect 
genetic variants in the coding region of the human genome that comprises 1.5 % of the total 
genomic  sequence.  Sequencing  of  the  whole  genome  will  identify  variants  in  introns  and  
intergenic regions containing regulatory elements. Exome sequencing is considered 
particularly useful for detecting rare mutations specifically in monogenic disorders. It can 
also be applied to find rare genetic variants in common complex disorders like ASD. In this 
chapter I summarize the most significant results from exome sequencing studies in ASD. 
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O´Roak and colleagues (2012a) performed exome sequencing in 209 ASD families. 39 % of 
the disruptive mutations detected in ASD were located in genes related to -catenin-
chromatin remodeling protein networks. Recurrent protein altering mutations were 
observed in two genes CDH8 (chromodomain helicase DNA binding protein 8) and NTNG1 
(netrin G1). In addition to that, a mutation screen of candidate genes in larger patient 
material revealed protein altering de novo mutations in genes GRIN2B (glutamate [NMDA] 
receptor subunit epsilon-2 precursor), LAMC3 (Homo sapiens laminin, gamma 3) and SCN1A 
(Homo sapiens sodium channel, voltage-gated, type I, alpha subunit). 
Sanders and colleagues (2012) studied the exomes of 238 families, including 200 quartets. 
Non-synonymous de novo mutations occurred > 40 % more frequently in affected individuals 
than in unaffected siblings. Disruptive de novo point mutations in the SCN2A (sodium 
channel protein type 2 subunit alpha) gene showed significant association with ASD. When 
the authors combined the sequencing data with an earlier study (O´Roak et al. 2012a) two 
more genes KATNAL2 (katanin p60 subunit A-like 2) and CDH8 (chromodomain helicase DNA-
binding protein 8) also met this criterion for an ASD risk gene.  
In the exome sequencing study of Neale and colleagues (2012), 175 ASD trios were 
investigated. 46 % of the cases had a missense or nonsense de novo variant. However, this 
rate was only modestly higher than the mutation rate expected in unaffected individuals. In 
contrast, proteins encoded by the genes that harboured the de novo missense or nonsense 
mutations showed connectivity to ASD related genes supporting protein-protein interaction 
as an important mechanism in ASD.  Again, the genes associated with ASD were CDH8 and 
KATNAL2. A new de novo splice site mutation in the SCN2A gene was subsequently detected 
in one additional ASD case. 
The studies mentioned here demonstrate significant association of three genes with ASD; de 
novo mutations at the CDH8, KATNAL2, and SCN2A genes contribute  to  risk  for  ASD.  They  
also suggest a polygenic model for ASD. De novo point mutations were overwhelmingly often 
located  on  the  paternal  chromosome,  and  were  associated  with  paternal  age.  Children  of  
older fathers had a modestly increased risk to develop ASD (Neale et al. 2012, O´Roak et al. 
2012a, Sanders et al. 2012).  Maternal age had positive correlation with ASD risk in one of 
the studies (Neale et al. 2012). A recent Icelandic next generation sequencing study 
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confirmed the observation that the father´s age is associated with the rate of de novo
mutations  of  the  child  (Kong  et  al.  2012).   This  is  in  line  with  the  mechanism  of  human  
spontaneous mutation; in males the mutation rate is much higher than in females mainly 
because there are more germ-cell divisions in sperm than in egg, and the difference 
increases with age (Crow et al. 2000). 
In addition to the previously mentioned studies, a recent exome sequencing study in 343 
ASD families reported that many of the disrupted genes are associated with the fragile X 
protein, FMRP. This strengthens the links between autism and synaptic plasticity (Iossifov et 
al. 2012). Also, gene-disrupting mutations (nonsense, splice site and frame shifts) were 
detected twice as frequently in affected versus unaffected children.  
Targeted sequencing of limited regions in the genome with a large sample set is a cost-
effective approach to detect rare variants in ASD. O´Roak and colleagues (2012b) performed 
targeted sequencing for 44 candidate genes in 2,446 ASD probands. They reported that 
recurrent disruptive mutations in six genes; CDH8, DYRK1A (dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 1A), GRIN2B, TBR1 (T-box, brain, 1), PTEN (phosphatase 
and tensin homolog) and TBL1XR1 (transducin (beta)-like 1 X-linked receptor 1) may 
contribute to 1 % of sporadic ASD. 
The results of exome sequencing studies together with CNV data indicate extensive locus 
heterogeneity but also provide targets for future diagnostics and therapeutics. There are 
many challenges and limitations with current methods of direct functional testing of rare 
variants and identifying alleles with modest effects. Ongoing next-generation sequencing 
studies by large international Autism consortiums might reveal disruptive mutations at 
regulatory regions. It likely will also give new information about small and disruptive 
structural variations in intergenic regions.  It is challenging to distinguish pathogenic from 
benign de novo mutations when the mutation is located outside of the coding region. 
Systematic collecting and sharing of mutation and phenotype data internationally will help 
to understand the non-coding part of the genome (Veltman and Brunner 2012). 
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3 AIMSOFTHESTUDY
The purpose of this thesis was to detect genetic variants predisposing to autism spectrum 
disorders in Finnish ASD families. Several different approaches were used in this thesis 
including linkage and candidate gene analysis, GWA study, CNV detection and promoter 
analyses. 
The specific aims of the study were: 
1. To fine map Xq11.1-q21.33 and sequence the coding areas of the RPS6KA6, ZNF711, 
ACSL4, DLG3, and IL1RAPL2 genes in the region (I). 
2. To analyze if SNPs previously detected in ASD (AGP 2007) in chromosomal regions 
9p24 and 11p12-13 and SNPs earlier reported in association with OCD at glutamate 
transporter gene SLC1A1 at 9p24 are associated with ASD in Finnish sample (II). 
3. To analyze the role of ProsSAP1A (isoform of SHANK2 gene) as a predisposing gene in 
autism (III). 
4. To  perform  a  genome-wide  scan,  promoter  and  pathway  analyses  in  novel  set  of  
Finnish ASD families (IV). 
5. To identify CNVs in Finnish data set (unpublished). 
Material and methods 
53
4 MATERIALSANDMETHODS
4.1 PATIENTMATERIAL
The original family material in Studies I and III was obtained mainly via Helsinki University 
Hospital,  Jyväskylä  Central  Hospital  and  Kuopio  University  Hospital.  The  second  set  of  
families, in Studies II and IV were collected through the Department of Child Neurology, 
Helsinki University Hospital in 2007-2008. Diagnostic evaluations were made by a multi-
disciplinary group of clinicians at the neurological department of each of the hospitals.  
Initially, patients were referred from outpatient clinics to the child neurological departments 
for a one to two weeks observation period. Thorough clinical and medical examinations 
were performed including neurological examinations, assessment of developmental history 
as well as psychological and neuropsychological examinations. Final diagnoses were based 
on ICD-10 (World Health Organization 1993) and DSM-IV (American Psychiatric Association 
1994) diagnostic nomenclatures. Childhood Autism Rating Scale (CARS) (Chopler et al. 1980), 
Asperger Syndrome Screening Questionnaire (ASSQ) (Ehlers and Gillberg 1993), and 
Asperger´s Syndrome Diagnostic Interview (ASDI) (Gillberg et al. 2001) were used as 
screening instruments.  Families with associative medical conditions such as Fragile X 
syndrome, chromosomal aberrations, neurocutaneous syndromes and profound mental 
retardation were excluded. 
Because the diagnostic tools for autism vary between different countries, the diagnostic 
methods used in Finland have been validated. 115 subjects who were originally recruited for 
the first Finnish molecular genetic study in autism (Auranen et al. 2002) were included in the 
validation  study  (Lampi  et  al.  2010).  Diagnoses  of  subjects  with  infantile  autism  were  re-
assessed using the international Autism Diagnostic Interview – Revised (ADI-R) questionnaire 
(Lord  et  al.  1994),  the  gold  standard  of  the  field.  Overall,  ADI-R  showed  96  %  consistency  
with the original diagnoses of the Finnish autism sample (Lampi et al. 2010).   
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Families and individuals included in this study are summarized in Table 4. The different study 
samples are described in more detail below, and in the original articles (I-IV). 
Table 4. Summary of family sets and individuals used in this study. 
Study Families Individuals Cases Controls Autism AS
I 99a 356 x 100 117 15
II x x 175 216 139 36
IIIb x x 455 431 x x
IIIc x x 851 1090 x x
IV 81 257 81 750 78 12
IVd 205 737 x x 241 0
aFamilies as in the study of Ylisaukko-oja et al. (2005) 
bFinnish samples as in Study I 
cResults were integrated with those reported by Berkel et al. (2010) 
dthe AVPR1A gene was studied in a larger set of families in Study IV 
AS = Asperger syndrome 
In Study I, fine mapping of the X-chromosome was performed in 99 Finnish ASD families, 
each containing one to three affected members with ASD. Families consisted from those in 
the publication of Ylisaukko-oja et al. (2005). The total number of individuals included in the 
study was 356, of which 117 were affected with infantile autism. Individuals with a diagnosis 
of autism were classified into liability class 1, the narrow diagnostic category, and LC2 a 
broader phenotype, which includes cases with both infantile autism and Asperger syndrome. 
All families were Finnish, except one father who is of Turkish origin. Forty-two affected 
males were selected for candidate gene analysis. In the families contributing to linkage at 
Xq21-24, we chose affected individuals sharing a haplotype not present in unaffected 
individuals of the family. All individuals included in the candidate gene analysis were males. 
The control sample set was comprised of 100 anonymous Finnish blood donors. 
In  Study II,  the patient material  consisted of  a  novel  set  of  Finnish families  comprising 175 
patients with ASD. 139 individuals had infantile autism and 36 individuals had AS. 138 of the 
ASD patients were men and 37 were women. The control material consisted of 216 
anonymous Finnish blood donors.  
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In Study III, the SHANK2 gene was sequenced in 455 patients with ASD and in 431 controls. 
The study material was recruited by the Paris (Paris Autism Research International Sibpair) 
study at specialized clinical centres disposed in France, Sweden, Germany, Finland and UK. 
The Finnish samples are the same as in Study I. 100 anonymous Finnish blood donors were 
included in the control material. 
In Study IV, a total of 83 Finnish families participated in the study, including 257 individuals 
in  total.  The  sample  set  was  included  in  Study  II  as  well.  The  families  contained  1  to  3  
affected members, 78 affected with infantile autism and 12 with Asperger syndrome. Within 
affected individuals the male-female ratio was 5:1. The families were analyzed using the 
IlluminaHumanOMNI 12 v.1.0 panel consisting of 733 000 single nucleotide polymorphisms 
(SNPs). The candidate gene AVPR1A in Study IV was genotyped in a larger set of families with 
autism (N=205) consisting altogether of 737 individuals. 
No phenotype data was available for the anonymous blood donors used as controls in 
Studies I-III. Thus they are used as population controls. In Study IV, the population based 
control material consisted of 750 unrelated subjects from a cohort of the Health 2000 Study, 
where genetic risk factors of metabolic syndrome (MetS) are studied (Kristiansson et al 
2012). In the control subjects DSM-IV mental disorders; alcohol use, depression and anxiety 
were excluded using the Composite International Diagnostic Interview (CIDI) (Pirkola et al. 
2005). Psychotic disorders were excluded using the research version of the Structured 
Clinical Interview for DSM-IV (SCID-1) (Perälä et al. 2007).  
The studies have been approved by the Ethical Committee of the Hospital of Children and 
Adolescents, Helsinki University Central Hospital. The Ethical Committee of the Finnish Red 
Cross Blood Transfusion Services in Helsinki approved the use of the DNA of anonymous 
blood donors. The Board of Health 2000, The National Institute for Health and Welfare has 
given  permission  for  control  samples  in  Study  IV.  Informed  written  consent  was  obtained  
from the subjects and/or their parents.  
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4.2 METHODS
All the methods used in this study have been described in detail in the original articles (Table 5). An 
overview of the methods is also given below.
Table 5. Methods used in this study. 
Method Reference Publication(s)
Experimental procedures
DNA extraction Gentra systems, Minneapolis, MN, 
US 
I, II, III, IV
Polymerase Chain Reaction 
(PCR) 
Kleppe et al. (1971) I, II, III
Electrophoresis, ABI 3730 Applied Biosystems, Foster City, CA, 
US 
I,II,III
7500 fast real-time PCR
System 
Applied Biosystems, Foster City, CA, 
US 
II
Genome wide SNP 
genotyping; Illumina 
Infinium Human 
OmniExpress-12v1 bead chip
Illumina, San Diego, CA, US IV
Illumina Infinium HD 
Human610-Quad BeadChip
Illumina, San Diego, CA, US IV
qPCR: CFX96TM Real-Time 
PCR System 
Bio-Rad Laboratories, Hercules, CA,
US 
IV
Analysis programs
Genemapper 4.0 Applied Biosystems, Foster City, CA, 
US
IV
Ingenuity Pathway Analyses IPA; Ingenuity systems IV
Promoter analysis; Transfac Matys et al. (2003) IV
Sequencher 4.7 Gene Codes, Ann Arbor, MI, US I, II, III
Statistical methods and 
software 
FBAT Horvath et al. (2001) II, IV
PEDCHECK 1.1 O’Connell and Weeks (1998) I, II, IV
MLINK Lathrop et al. (1984), Lathrop et al. 
(1986)  
I
HOMOG Ott (1986) I
MERLIN 1.0.1 MINX Abecasis et al. (2002) I
PLINK Purcell et al. (2007) II, IV
Blosum62 Styczynski et al. (2008) I
PolyPhen Ramensky et al. (2002) I
SIFT Ng and Henikoff (2003) I
SPSS 15.0 SPSS Inc., Chicago, IL, US II
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4.2.1 DNAisolationandgenotyping
Genomic DNA from the samples used in Studies I and III was extracted from EDTA-treated 
peripheral blood samples with the Puregene DNA purification system (Gentra Systems, 
Minneapolis, MN, US) according to the manufacturer´s protocol or using a phenol-
chloroform protocol modified from Vandenplas and colleagues (1984). DNA from blood 
samples of new sample material collected in years 2007-2008 were extracted using the 
HUSLAB protocol MP025 non-enzymatic DNA extraction method with a slight modification; 
Igepal was used to disrupt cell membranes instead of nonident. 
In Studies I, II and III primer sequences were designed using the Primer3 program. The DNA 
of  the  study  subjects  was  amplified  by  polymerase  chain  reaction  (PCR).  The  polymerase  
chain reaction conditions were as follows: 10 or 5 min at 94°C followed by 35 cycles of the 
denaturation step: 30 s at 94°C, annealing step: 30 s at temperature specific for each primer 
(50-65°C), the elongation step: 30 s at 72°C and final extension for 10 min at 72°C. 
Sequencing was performed using cycle sequencing with the Big Dye Terminator kit (ABI, 
Foster  City,  CA,  USA)  and  reactions  were  run  on  an  ABI  3730  capillary  sequencer.  SNP  
genotyping in Study II was performed with a 7500 fast real-time PCR system (Applied 
Biosystems, Foster City, CA, US) according to manufacturer´s instructions. 
Microsatellite  markers  in  Studies  I  and  IV  were  selected  from  the  Marshfield  Medical  
Research Foundation map and Primer sequences were obtained from UCSC Genome 
Browser. Forward primers were labeled at the 5’-end with FAM or PET fluorescent dye. PCR-
products  were  pooled  and  electrophoresed  on  an  ABI3730  automatic  DNA  sequencer.  
Genotypes  were  assigned  using  Genemapper  4.0  software  (ABI,  Foster  City,  CA,  USA).  All  
microsatellite  and  SNP  markers  used  in  this  study  (Studies  I,  II,  IV)  were  checked  and  
corrected for Mendelian errors prior to analysis using the Pedcheck program (O'Connell and 
Weeks 1998). 
Genome wide SNP genotyping of ASD families was performed using the Illumina Infinium 
Human OmniExpress-12v1 bead chip (www.illumina.com) consisting of 733 202 markers. The 
genotyping of Health 2000 control material was performed with the Illumina Infinium HD 
Human610-Quad BeadChip.
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We used quantitative PCR to validate the CNVs detected in Study IV. SYBR green-based 
genomic real-time qPCR analysis  was performed on a CFX96TM Real-Time PCR System (Bio-
Rad Laboratories, Hercules, CA, US) by using SsoFastTM EvaGreen® Supermix (Bio-Rad 
Laboratories, Hercules, CA, US) according to the cycling protocol. Primers were developed by 
the Primer3 program (http://frodo.wi.mit.edu/) (Rozen and Skaletsky 2000). qPCR 
quantifications were performed in duplicate on 1 ng/l DNA and included a water control. 
Copy numbers were measured relative to the reference gene, zinc finger protein 80 (ZNF80).
4.2.2 AnalysisPrograms
In  Study  IV  the  networks  and  functional  analyses  were  generated  through  the  use  of  IPA  
(Ingenuity® Systems, www.ingenuity.com).  IPA  is  a  web-based  software  application  that  
transforms a list of genes into a set of networks based on the Ingenuity Pathways Knowledge 
Base, a large dataset which contains biological and chemical relationships extracted from 
scientific literature. IPA enables user to analyse, integrate and understand the experimental 
data  derived  from  SNP  microarrays,  gene-expression,  microRNA,  proteomics  and  other  
experiments which produce a list  of  genes or  chemicals.  The goal  of  IPA is  to discover and 
visualize hidden causal connections of the dataset of interest (www.ingenuity.com).
In Study IV we used Transfac® to predict transcription factor (TF) binding sites. Transfac® is a 
knowledge-base containing published data on eukaryotic transcription factors, their target 
genes and regulatory binding sites  (Matys et  al.  2003).  The goal  of  the transcription factor  
binding analyses is to better understand the mechanism of regulation and to characterize 
the mutations disrupting the regulatory mechanisms. In this thesis neurospecific TF binding 
sites were predicted with the algorithm Match in the Transfac® database (www.biobase.de). 
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4.2.3 Statisticalgeneticanalyses
In Study I linkage analysis was performed using the MLINK (Lathrop et al. 1984, Lathrop et al. 
1986), HOMOG (Ott 1986) and MERLIN 1.0.1 MINX (Abecasis et al. 2002) programs. In 
Studies  II  and  IV  allelic  association  analyses  were  done  by  FBAT  (Horvath  et  al.  2001)  or  
PLINK (Purcell et al. 2007). In Study IV all quality checks of the genome wide SNP data were 
performed using PLINK software. Genotypes were checked for correct Mendelian 
transmission  when  family  information  was  available.  To  exclude  sample  swaps  and  
contamination, gender checks were performed, and the samples monitored for identical-by-
descent (IBD) sharing and mean heterozygosity. For the analysis of the genome-wide scan, 
markers were pruned for too low minor allele frequency (MAF <0.05), missing genotype 
frequency  (if  over  5  %  of  marker  genotypes  were  missing)  and  HWE  (p-value  <  0.001  in  
controls). Subjects were pruned out if they had more than 5% of their genotypes missing and 
if they were of non-Finnish origin.  
In Study IV we used PLINK for both the TDT analyses within the autism families and for the 
case-control association analysis. The rationale for using these two approaches for 
association is that the methods are concerned with slightly different aspects of heredity; the 
TDT measures linkage in the presence of association, observing transmissions of alleles from 
heterozygous parents to affected offspring, whereas case-control association simply 
measures whether a particular allele is more common in the cases than in the controls. 
While TDT is not sensitive for population stratification contrary to the case-control setting, 
the case-control study is better at finding common risk alleles. Thus, the approaches 
complement each other. 
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CNV calls and analysis is based on build GRCh37/hg19 of the human genome reference 
sequence (UCSC Genome Browser on Human Feb. 2009). Two different algorithms PennCNV 
(Wang et al. 2007) and QuantiSNP (Colella et al. 2007) were used for the identification of the 
CNVs. Only the calls consistent between both the algorithms were used for further analysis, 
to  minimize  the  rate  of  false  discoveries  (Dellinger  et  al.  2010,  Pinto  et  al.  2010).  As  the  
impact  of  rare  CNVs  on  ASD  predisposition  has  been  established  (Pinto  et  al.  2010),  we  
chose to analyze only rare, possibly pathogenic CNVs. Rare CNVs were extracted by 
excluding all the common CNVs based on the CNV frequencies in the Finnish control 
population (> 1% frequency). Controls were the same as in study IV. The AutismKB 
(http://autismkb.cbi.pku.edu.cn/) database was used to determine the novelty of ASD 
candidate CNVs.  
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5 RESULTSANDDISCUSSION
5.1 Finemapping and sequencing of candidate genes at Xq11.1-q21.33 (I and
unpublisheddata)
In a previous genome-wide scan of 369 microsatellite markers in 38 Finnish families with 
ASD (Auranen et al. 2002), one of the positive loci was observed at the X chromosome, the 
best marker DXS7132 locating at Xq11.1. Further analysis of the region in a larger sample set 
resulted  in  the  highest  LOD  score  (Zmax=2.39)  at  DXS7117  at  Xq13.1  (Ylisaukko-oja  et  al.  
2005). As many of the patients with ASD have intellectual disability and the linked region 
contained several causative genes for ID we performed fine mapping of Xq11.1-q21.33 with 
a total of 26 microsatellite markers. 
 A maximum two-point LOD score of 3.00 was obtained at DXS1225 on Xq21.1 using a broad 
phenotype  (LC2)  and  dominant  model  (Figure  9).  The  highest  multipoint  LOD  score  was  
obtained with the same marker DXS1225 (HLOD=2.94, NPLall=3.43 corresponding to 
P=0.0004). In concordance with the two-point analysis, the dominant inheritance model 
yielded the best results. Thus, the region of interest shifted distally from DXS7132 at Xq11.1 
to  DXS1225  at  Xq21.1  (hg  18).  There  were  numerous  genes  in  the  linked  region  that  are  
related to XLID.   Of  them RPS6KA6 (ribosomal protein S6 kinase alpha-6) and ZNF711 (zinc 
finger protein 711) (Yntema et al. 1999, Tarpey et al. 2009) reside at the peak region, ACSL4
(acyl-CoA synthetase long-chain family member 4) and DLG3 (discs, large homolog 3), which 
have previously been known to cause XLID (Tarpey et al. 2004, Renieri et al. 2005, Zanni et 
al. 2010) and IL1RAPL2 (interleukin 1 receptor accessory protein-like 2), a homologous gene 
for IL1RAPL1 that is mutated in autism (Piton et al. 2008, Piton et al. 2011) and intellectual 
disability with autism (Bhat et al. 2008).  
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Figure 9. The locations of the linkage peaks on chromosome Xq in this and earlier studies. 
The locations of candidate genes sequenced in this study are also presented. 
 We sequenced the coding regions and splice sites of the aforementioned five candidate 
genes in 42 male patients with infantile autism from families contributing to the linkage. We 
could not establish any functional mutations in these patients who carried a haplotype not 
shared by unaffected individuals in the family. One non-synonymous variant was detected at 
the RPS6KA6 gene. Prediction analysis showed that it was a harmless variant. This implies 
that the coding sequence variants of these five genes may not explain the linkage observed 
in our data set. The current study design cannot exclude the existence of rare mutations in 
these genes in the Finnish sample. Recently, Piton et al. (2011) performed a systematic re-
sequencing of X-chromosomal synaptic genes in ASD (N=142) and schizophrenia (N=143). 
The gene set included the DLG3, IL1RAPL2 and RPS6KA6 genes. None of the variants they 
detected in these three genes were likely to be involved in ASD (Piton et al. 2011).  
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Causative mutation in neuroligin3 (NLGN3) at Xq13 has been reported in autism (Jamain et 
al. 2003). In previous Finnish scan of Xq (Ylisaukko-oja et al. 2005) NLGN3 was sequenced in 
the same data set used in this study. Disruptive mutations were not detected. There are 
several other genes in the linkage area which are highly expressed in the brain. Sequencing 
of the whole Xq11.1-q21.33 region is necessary to reveal autism related X-chromosomal 
mutations in our dataset. Sequencing of the coding region of the X-chromosome has 
revealed a number of novel causative mutations for XLID. Altogether 105 genes have been 
found underlying XLID (http://www.ggc.org/research/molecular-studies/xlid.html)
(November 2012). Based on the current knowledge of the partially shared genetic 
background of autism and ID, these genes serve as candidate genes for autism. 
Chromosomal aberrations at Xq21 were analyzed from genome wide SNP data used in Study 
IV. Two of the patients had a CNV at the Xq21.31 region containing PCDH11X/Y 
(protocadherin 11 X/Y-linked gene) (Figure 10). PCDH11X/Y gene  belongs  to  the  
protocadherin family. PCDH11X/Y genes are present on both the X and Y chromosomes, and 
are  expressed  in  the  cortex  of  the  human  brain.  In  our  study  a  male  patient  (3076)  with  
infantile autism had a 580 kb paternally inherited duplication at the X chromosome and a 
446 kb duplication at the Y chromosome which both contain parts of the PCDH11X/Y gene.
The male patient also had a 115 kb intronic X-chromosomal de novo duplication in the same 
gene region. Female patient (1872) with infantile autism had a 137 kb intronic de novo
deletion in the PCDH11X gene. In earlier studies of autism, two CNVs at PCDH11X have been 
detected  (Pinto  et  al.  2010).  Disruption  of  the  PCDH11X gene has also been described in 
language delay (Speevak and Farrell 2011). Association studies of the PCDH11X gene in late-
onset Alzheimer disease have been conflicting (Carrasquillo et al. 2009, Beecham et al. 
2010). The Y chromosomal CNVs we detected were novel according to the AutismKB. 
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Figure 10. CNVs detected in patients with autism on gene PCDH11X.
The PCDH11X/Y genes, like the other members of the protocadherin family, play a major role 
in synaptogenesis, the formation of functional synapses (Kim et al. 2011). PCDH11Y is one of 
the rare genes on the Y chromosome and it is specific to humans (Blanco et al. 2000). 
PCDH11Y may play a role in human specific cognitive functions, such as language; therefore 
the defects in this gene could predispose to neuropsychiatric disorders (Durand et al. 2006).    
Previous studies of ID have reported that not all of the truncating mutations identified are 
causative. Tarpey et al. (2009) observed that 1 % of the protein-truncating mutations on the 
X chromosome were found to be unrelated to disease. Furthermore, Najmabadi et al. (2011) 
reported that 12 of the observed inactivating mutations did not co-segregate with ID. More 
experimental studies are warranted to see if the detected mutations have an effect for the 
phenotype studied. Considering autism, presumably the interaction of the disrupted genes 
predispose to autism, while one single mutation is not sufficient.   
5.2 Analysisof9p24and11p12-13regionsinASD(IIandunpublisheddata)
In  Study  II  we  analyzed  whether  the  most  significant  SNPs  reported  in  the  largest  linkage  
study of ASD (Szatmari et al. 2007) at chromosomal areas 9p24 (rs1340513 and rs722628) 
and 11p12-13 (rs1358054 and rs1039205) are associated with ASD in the Finnish sample. 
Furthermore, considering the common genetic background of ASD and obsessive compulsive 
disorders  (OCD),  we  studied  SNPs  in  the  SLC1A1 gene at 9p24, which has been previously 
associated with OCD (Dickel et al. 2006, Stewart et al. 2007). 
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The SNPs associated with ASD at the 9p24 region are presented in Figures 11 and 12. SNPs 
rs1358054 and rs1039205 at the chromosomal region 11p12-13 did not show association 
with ASD in the Finnish sample. The strongest association was detected with SNP rs1340513 
in the JMJD2C alias KDM4C gene at 9p24.1 (P=0.007, corrected P=0.011). A recent large 
GWA study in OCD detected association in the JMJD2C gene, although none of the studied 
SNPs  reached  genome-wide  significance  at  9p24  (Steward  et  al.  2012).  In  this  thesis,  we  
observed that one female subject (1492) with Asperger syndrome had an inherited, 
homozygous 4.7 kb deletion which located 15 kb from JMJD2C to the 5` direction that might 
affect  the  regulation  of  this  gene.  In  the  Finnish  controls,  CNVs  in  this  region  were  not  
detected. Another CNV has been detected in an earlier study in JMJD2C in autism (Pinto et 
al. 2010) (Figure 12).  
The product of the JMJD2C gene is a histone demethylating enzyme, which converts 
trimethylated histone residues to the dimethylated form and thus affects chromatin 
structure and gene transcription (Cloos et al. 2006). JMJD2C is highly expressed in the brain 
(Nagase et al. 1998) and aberration of its expression level has been detected in autistic 
patients compared to controls (Hu et al. 2009). Genes affecting histone demethylation and 
chromatin structure have been reported in ASD, for example MECP2 underlying Rett 
syndrome. 
We observed a possible gene x gene epistatic interaction between SNPs rs2228622 at 
SLC1A1 and rs1340513 at JMJD2C with SPSS logistic regression (P=0.002). We also noticed 
that SNP rs2228622 in the SLC1A1 gene was also associated with heavy routines and rituals 
(P=0.0026). The study was however limited by the small sample size of individuals with 
known endophenotypes, warranting a replication of the result in bigger material. In another 
recent study, SNP rs301430 located in the SLC1A1 gene was associated with anxiety but not 
in repetitive behavior in children with ASD (Gadow et al. 2010). This is in line with our study 
where this SNP did not show association with repetitive behavior. In addition to these, some 
evidence for association of rs301979 in SLC1A1 in male patients with autism has been 
reported (Brune et al. 2008). Several  SNPs have shown association with OCD (Arnold et  al.  
2006, Dickel et al. 2006, Stewart et al. 2007, Shugart et al. 2009, Wendland et al. 2009, 
Samuels  et  al.  2011).  The  strongest  association  with  OCD  in  the  SLC1A1 region has been 
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found at rs301443 (P=0.000067) residing 7.5 kb outside at the 3´ end of the SLC1A1 gene 
(Shugart et al. 2009). Variations reported to be associated with ASD at SLC1A1 in this thesis 
and by others or with OCD are presented in Figure 11. In this thesis one male subject (1946) 
with autism had paternally inherited a 168 kb duplication on the glutamate transporter 
SLC1A1 gene. He had childhood autism and ritualistic behavior. 
Figure 11. Locations of variants associated with ASD or OCD are presented: 1. In this thesis 
patient 1946 had a paternally inherited 168 kb duplication on the SLC1A1 gene,  2.  SNP  
rs2228622 was associated in heavy routines and rituals in ASD (P=0.0026), 3. 420 kb 
inherited duplication in autism (Bremer et al. 2011), 4. 31 kb inherited deletion in autism 
(Pinto et al. 2010), 5. SNP rs301430 was associated in anxiety in ASD (P=0.01) (Gadow et al. 
2010), 6. rs301979 was associated in ASD (P=0.01) (Brune et al. 2008), SNPs associated in 
OCD are 7. rs3933331 in hoarding (P=0.005) (Wendland et al. 2009), 8. rs4740788 (P=0.003) 
(Samuels et al. 2011), 9. rs2228622, males only (P=0.045) (Steward et al. 2007), 10. rs301443 
(P=0.000067) (Shugart et al. 2010), 11. rs3780412, males only (P=0.002) (Dickel et al. 2006), 
12. rs3780412, males only (P=0.045) (Steward et al. 2007), 13. rs301430 (P=0.03) (Dickel et 
al. 2006), 14. rs301434 (P=0.006) and rs301435 (P=0.03) (Arnold et al. 2006). 
Interestingly, we also detected a significant association of two SNPs to ASD at chromosomal 
region 9p23-24 in Study IV. There, the most significant results were obtained at the 9p23 
region at the PTPRD gene which is located only 1.2 Mb from JMJD2C (Figure 12). The 
strongest associations were found with SNP rs16926616 (5.7x10-5, assoc) locating 292 kb 
from the PTPRD gene and SNP rs324484, (P=1.1x10-3, TDT) at PTPRD. In an earlier, large 
GWA study in autism a significant association was detected between genes JMJD2C and 
PTPRD (Weiss et al. 2009). The PTPRD gene has been associated with restless legs syndrome 
(Schormair et al. 2008), ADHD (Elia et al. 2010) and OCD (Steward et al. 2012). Furthermore, 
the postsynaptic IL1RAPL1 gene that is associated with intellectual disability and autism 
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mediates synapse formation by trans-synaptic interaction with pre-synaptic PTPRD (Yoshida 
et  al.  2011).  Figure  13  illustrates  the  overview  of  the  locations  of  the  best  SNPs  at  9p24  
which were associated with ASD in this thesis. 
Figure  12.  Variants  associated  with  ASD  in  this  thesis  or  by  others  in  the  KDM4C/PTPRD
region. 1. One patient with Asperger (1492) had inherited a homozygous 4.7 kb deletion 
from  both  parents  15  kb  from  JMJD2C to the 5`direction, 2. rs1340513 at KDM4C was 
associated in ASD (P=0.007) in Study II, 3. rs324484 at PTPRD and 4. rs16926616 near PTPRD
were  associated  in  ASD  in  Study  IV  (P=1.1  x  10-3 and P=5.7 x 10-5 respectively). Previous 
studies reported 5. one deletion in autism at KDM4C (Pinto et al. 2010), 6. rs1340513 
associated with ASD (P=0.0007) (Szatmari et al. 2007), 7. rs4742409 associated with ASD 
(P=1.6 x 10-5)  (Weiss  et  al.  2009),  8.-22.  Several  deletions  at  the  PTPRD gene (Pinto et al. 
2010, Gai et al. 2012, Levy et al. 2011, Sanders et al. 2011). 
Results and discussion 
68
Figure 13. SNPs associated in ASD in Study I (black) and Study IV (blue). 
In addition to the SLC1A1 gene, we identified several other glutamate genes containing CNVs 
in ASD patients. Four of the patients (1490, 1869, 1890 and 2923) had a 7.8 kb deletion at 
11q14.3 in the GRM5 gene (Homo sapiens glutamate receptor, metabotropic 5); three of 
them  had  autism  and  one  had  Asperger  syndrome.  Based  on  AutismKB  this  CNV  has  not  
been detected in ASD before. L-glutamate is the major excitatory neurotransmitter in the 
central nervous system and activates both ionotropic and metabotropic glutamate 
receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain 
function and can be perturbed in many neuropathologic conditions. The metabotropic 
glutamate receptors belong to a family of G protein-coupled receptors that affect signal 
transduction  (Ozawa  et  al.  1998).  Group  I  includes  GRM1  and  GRM5  and  these  receptors  
have  been  shown  to  activate  phospholipase  C.  Group  II  contains  GRM2  and  GRM3  while  
Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to 
the inhibition of the cyclic AMP cascade but differ in their agonist selectivity. Deletions in 
GRM5 were discovered earlier in patients with attention-deficit hyperactivity disorder 
(ADHD) (Elia et al. 2010, Elia et al. 2011).  
Other glutamate related genes located in CNV regions observed in this study were GRID1 
(glutamate receptor, ionotropic, delta 1), GRIK1 (glutamate receptor, ionotropic, kainate 1) 
and GRIN2A (glutamate receptor, ionotropic, N-methyl D-aspartate 2A). One of the patients 
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had a 4 kb deletion at 10q23.2 located at the GRID1 gene. This gene encodes a subunit of the 
glutamate receptor channels that mediate most of the fast excitatory synaptic transmission 
in the central nervous system and play a key role in synaptic plasticity. A 4.5 kb deletion at 
21q21.3 located at GRIK1 was detected in one of the patients (2994). In another case-control 
and family-based study, nominal significant association was observed between single 
nucleotide polymorphisms of GRIK1 and  schizophrenia  (Hirata  et  al.  2012).  In  this  thesis  a  
111 kb deletion at 16p13.2 was detected in one of the patients (2964), located 139 kb from 
the gene GRIN2A to the 5´direction.  The  GRIN2A  receptor  is  found  at  excitatory  synapses  
throughout the brain and it has an important role in neuronal activity and development. 
Mutations in this gene are involved in intellectual disability and learning difficulties (Endele 
et al. 2010). GRIN2A is also associated with autism (Barnby et al. 2005, De Krom et al. 2009). 
Results and discussion 
70
5.3 GeneticandfunctionalanalysesofSHANK2mutationsprovideevidencefor
multiplehitmodelofASD(III)
In order to better understand the role of the NRXN-NLGN-SHANK pathways in ASD, we 
screened for SHANK2 CNVs and coding mutations in ASD cases and controls collected from 
France, Sweden, Germany, Finland and UK. Furthermore, we analyzed co-occurrent CNVs in 
patients who had de novo SHANK2 deletions in this and earlier studies (Berkel et al. 2010, 
Pinto et al. 2010). 
The human SHANK2 gene (NM_012309.3) contains 25 exons and spans 621.8 kb. 
Transcription of SHANK2 produces 4 isoforms: SHANK2E (AB208025), ProSAP1A (AB208026), 
ProSAP1 (AB208027) and AF141901 from three distinct promoters. In this study, these 
isoforms were validated by RT-PCR and sequencing. We noticed that SHANK2 isoforms are 
differentially expressed in human tissues. Inter-individual differences in the relative amount 
of mRNA between isoforms of the gene have been previously reported in other synaptic 
genes such as NLGN1-4Y, PCDH11X/Y and SHANK3 (Jamain et al. 2003, Durand et al. 2006, 
Durand et al. 2007). Exons 19, 20 and 23 were found to be expressed only in the brain in all 
individuals tested. This kind of brain specific splicing has been observed earlier in exon 18 of 
SHANK3 (Durand et al. 2007), which is similar to exons 19 and 20 in SHANK2.
For the detection of CNVs affecting SHANK2 we genotyped an independent sample of 260 
patients with the Illumina 1 M Duo SNP array. A 41.2 kb de novo deletion was found in one 
patient with autism and moderate ID. The deletion covered twelve exons (5-16) and altered 
all SHANK2 isoforms. In an earlier study, deletions of SHANK2 were found in one patient with 
ASD and in another with intellectual disability (Berkel et al. 2010). Furthermore, one 
additional SHANK2 de novo deletion was detected by the Autism Genome Project (Pinto et 
al. 2010). SHANK2 deletions were absent in more than 5000 controls and it is not listed in 
the  Database  of  Genomic  Variants  (http://projects.tcag.ca/variation/). Figure 14 illustrates 
the locations of the CNVs detected in the SHANK2 protein.  
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Figure 14. The locations of the CNVs disrupting the SHANK2 protein are presented. The 
longest SHANK2 isoform (SHANK2E, AB208025) contains ankyrin (ANK) repeats, SRC 
homology 3 (SH3) domain, postsynaptic density 95/Discs large/zona occludens-1 (PDZ) 
homology  domain,  Proline  rich  region  and  sterile  alpha  motif  (SAM)  domain.  Proline  rich  
region contains HOMER binding motif, dynamin-2 binding motif and contactin binding motif. 
The locations of conserved variants which reduced the number of synapses significantly are 
also shown. See text below. 
To screen additional mutations in SHANK2 we sequenced all exons of the longest SHANK2E
isoform in 230 patients with ASD and 230 controls. We also sequenced the ProSAP1A
isoform  that  corresponds  to  the  major  SHANK2 isoform in the brain in an additional 225 
patients and 201 controls.  
Three patients with ASD had a mutation within the SHANK2E isoform: two independent 
patients had R174C listed in dbSNP and the third one R185Q. No variants were identified in 
the control samples. Within the ProSAP1A isoform, we identified 24 non-synonymous 
variations. When our results were integrated with the results of Berkel et al. (2010), a total 
of 40 variants of ProSAP1A were identified. Three of them have previously been reported in 
dbSNP. There was no enrichment of rare variants of SHANK2 (MAF <1%) in patients with ASD 
compared with controls. Only two variants, Y967C and R569H, with MAF >1% were 
observed. Table 6 presents the variants detected in the ASD patients only. These were not 
detected in 1090 controls. 8 variants were detected in both ASD patients and controls, and 
17 variants in controls only. 
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Table 6. ProSAP1A/SHANK2 variations identified in ASD patients only.  
Exon Nucleotide Amino Acid Conservation in SHANK 
proteins 
Study
E11 G70344397A R405W Yes (SHANK1 & SHANK3) Berkel et al. 2010
E11 G70344284A R443C Yes (SHANK3) This study
E13 G70322214A P587S No Berkel et al. 2010
E14 C70222501A R598L Yes (SHANK3) This study
E17 C70026597A V717F Yes (SHANK1 & SHANK3) This study
E17 C70026561T A729T Yes (SHANK3) This study
E22 G70014059A R841X Yes (SHANK3) Berkel et al. 2010
E24 C70010562T E1162K No This study
E24 C70010538T G1170R Yes (SHANK1 & SHANK3) This study
E24 C70009920T V1376I No This study
E24 C70009920T V1376I No This study
E24 dup(AACGGT)
70009882–
70009887 
dup(LP)
1387–1388 
Yes (SHANK1 & SHANK3) Berkel et al. 2010
E24 G70009529A T1506M Yes (SHANK1 & SHANK3) Berkel et al. 2010
E24 C70009443T D1535N Yes (SHANK1 & SHANK3) This study
E25 A69997007G L1722P Yes (SHANK1 % SHANK3) This study
E25 C69996987T A1729T Yes (SHANK3) Berkel et al. 2010
Nucleotide positions are according to NM 012309.3 from NCBI36/hg18 on the positive DNA 
strand; The patients with ASD and the controls used for this analysis came from this study of 
Berkel et al. 2010 comprising altogether 851 ASD cases and 1090 controls. 
We observed a significant enrichment of variants affecting conserved amino acids in patients 
compared to controls. 80 % of variants detected only in the patient sample compared to 
only 35.3 % of these in the control sample affected conserved amino acids (Fisher´s exact 
test 1-sided, P=0.013, OR=6.83). Because several independent patients carried the 
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conserved variants we also tested the effect of carriers to enrichment. We noticed that 29 of 
851 patients (3.4 %) and 16 of 1090 controls (1.5 %) carried variants affecting conserved 
amino acids (Fisher exact test 1-sided, P=0.004, OR=2.37). 
All but one of the variants were predicted to be damaging with Polyphen2. The benign 
variant was found only in controls. To test the functional impact of SHANK2 variations we 
performed expression studies in neuronal cell cultures. All mutations identified in our first 
screen of 230 patients with ASD and 230 controls (N=16) were tested. Mutation sites were 
first introduced into rat ProSAP1A cDNA using the site directed mutagenesis kit (Stratagene) 
and confirmed by sequencing. After that cDNAs were tested for expression by Western blot 
analysis. As a result wild type showed over-expression compared to mutant ProSAP1A cDNA.
The effect of the variants was then investigated by transfecting the cDNAs into primary 
hippocampal neurons. Cell culture experiments of rat hippocampal primary neurons were 
performed as described previously (Boeckers et al. 2005). For the quantification of excitatory 
synapse number, cells were counterstained with anti-Bassoon antibodies. From randomly 
chosen transfected neurons, Bassoon positive spots from primary dendrites were counted 
and the length of dendrites was measured. The total number of spines was expressed as 
density per 10 mm length of dendrite. 
Variants affecting conserved amino acids were associated with a higher reduction of synapse 
density in vitro. Variant R818H was virtually absent outside Europe and had the highest 
allelic frequency (3 %) in Finland, but overall it´s frequency was not higher in patients with 
ASD (32/3250, 1 %) compared with controls (27/2030, 1.33 %). Almost 5 % of the Finnish 
population was heterozygous for this conservative variant which reduced the number of 
synapses in vitro.  After  Bonferroni  correction,  four  of  the  variants  could  be  shown  to  
significantly affect synaptic density. Of these variants, A729T, G1170R and L1722P were 
observed only in patients and S557N was identified more frequently in ASD than in controls. 
The locations of these variants in the SHANK2 protein are presented in Figure 14. Synaptic 
density was also tested as a continuous trait, which showed that variants identified in 
patients significantly decreased synaptic density in vitro, compared to the variants present in 
controls or both. Variants affecting conserved amino acids were associated in higher 
reduction of synapse density (P=0.004). 
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We  also  searched  if  three  patients  with  SHANK2 de novo deletion had additional CNVs 
elsewhere in the genome which could modulate the impact of SHANK2 deletions in the 
development of ASD. ASD patients with SHANK2 deletion analyzed here were AU038_3 (this 
study), 5237_3 (Berkel et al. 2010, Pinto et al. 2010) and 6391_3 (Pinto et al. 2010). Co-
occurrence of SHANK2 de novo deletions and inherited CNVs are presented in Table 7.  
Table 7. Additional CNVs containing ASD candidate genes detected in patients with SHANK2
deletion. 
CHR GENE AU038_3 5237_3 6319_3 
1q32.1 CAMSAP1L paternal dup - -
3p26.3 CNTN4 - - maternal del 
3q26.3 NLGN1 - maternal dup -
5q31.3 PCDHA1-10 - - paternal del 
6p25.3 DUSP22 - de novo del -
11q13 SHANK2 de novo del de novo del de novo del 
15q11.2 TUBGCP5 - - paternal del 
NIPA2 - - paternal del 
CYFIP1 - - paternal del 
NIPA1 - - paternal del 
WHAMML1 - - paternal del 
15q13.2 FAM7A1 maternal del maternal del -
FAM7A2 maternal del maternal del -
ARHGAP11B maternal del maternal del -
15q13.3 CHRNA7 maternal dup paternal dup -
All three individuals with autism who carry de novo SHANK2 deletions also have rare CNVs in 
15q11-13, a chromosomal region long associated with Angelman syndrome, Prader-Willi 
syndrome, ASD and other neuropsychiatric disorders. Patient 6319_3 is missing one copy of 
CYFIP1 (cytoplasmic  FMR1  interacting  protein),  a  gene  located  in  15q11-13.  It  codes  for  a  
protein  that  binds  FMRP,  the  protein  missing  in  Fragile  X  syndrome.  The  deletion  also  
contained genes NIPA1 (non-imprinted in Prader-Willi/Angelman syndrome 1), NIPA2 (non-
imprinted in Prader-Willi/Angelman syndrome 2), CYFIP1 and TUBGCP5 (tubulin, gamma 
complex associated protein 5). The deletion in this locus has been associated with 
schizophrenia, neurodevelopmental disorder, epilepsy and autism (Cooper et al. 2011, 
Stefansson et al. 2008). Patients AU038_3 and 5237_3 carry an extra copy of CHRNA7
(cholinergic receptor, nicotinic, alpha 7), a gene that encodes a receptor of the acetylcholine 
neurotransmitter. This locus at 15q13.3 has been tied to ID, epilepsy, schizophrenia and ASD 
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(International schizophrenia consortium 2008, Sharp et al. 2008, Helbig et al. 2009, Miller et 
al. 2009). 
Other additional CNVs detected in  patients with SHANK2 deletion contained ASD candidate 
genes including CAMSAP1L which codes calmodulin regulated spectrin-associated protein, 
CNTN4 (contactin 4), NLGN1 (neuroligin 1), protocadherin gene cluster PCDHA1-10 and 
tyrosine phosphatase coding gene DUSP22 (dual specificity protein phosphatase 22). 
Recent results of exome sequencing revealed one additional frame shift mutation in SHANK2 
(Sanders et al. 2012). Another study detected aberrations of SHANK2, CHRNA7 and also
ARHGAP11B (Rho GTPase activating protein 11B) in a patient with intellectual disability and 
language  impairment  supports  (Chilian  et  al.  2013).  Notably,  the  combination  of  the  
disrupted genes was the same as in this study. The identification of mutations in NRXN1, 
NLGN3/4X and SHANK2/3 strengthens the role of synaptic gene dysfunction in ASD. The 
NRXN-NLGN-SHANK pathway is associated with synaptogenesis, and imbalance between 
excitatory and inhibitory currents is a risk factor of ASD. It is currently unknown which or 
how  many  risk  factors  are  sufficient  to  contribute  to  ASD.  Co-occurrence  of  de novo
mutations, together with inherited variations might play a role in genetic susceptibility to 
ASD. All of the 15q CNVs in this study were inherited, whereas the SHANK2 deletions were 
spontaneous. For these patients, it is likely the genome cannot cope with the extra de novo
event and these variants together contribute to ASD.  
5.4 Genomewidescan,promoterandfunctionalanalysisinASD(IV)
In  Study  IV  we  performed  a  GWA  scan  in  a  novel  set  of  Finnish  ASD  families,  paired  with  
functional  analysis,  and  a  candidate  gene  based  analysis  of  epistasis  in  ASD.  In  order  to  
better understand the transcriptional regulation of the currently best known autism 
candidate genes, we performed an in silico analysis of their promoter sequences obtained 
from Genbank. In addition, we conducted association and promoter analyses of the autism 
candidate gene, AVPR1A. 
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5.4.1 Genome-widescanandepistasis
We performed a genome wide scan in 81 ASD families (N=257) with TDT. Each family had 1-3 
autistic individuals. In addition to TDT, we carried out a case-control association analysis, 
where the control material consisted of 750 unrelated Finnish individuals. The association 
and epistasis analysis were carried out with PLINK. The best associated genes from the TDT 
and case-control analyses are shown in Table 8. Epistatic effects were considered on a 
significance level of p-value  10-6.
Table 8. Top-results in TDT and case-control analyses.
LOCUS SNP P (TDT)* P (CASE-
CONTROL)** 
GENE NEAR GENE
2p23.3 rs12613835 - 8.3 x 10-5 DTNB
2q31.1 rs4668086 1.1 x 10-3 2.0x10-6 CERS6(LASS6) NOSTRIN
3p14.1 rs4855550 2.9 x 10-5 3.0 x 10-6 FOXP1, UBA3, ARL6IP5
5q21.3 rs902505 4.0 x 10-6 – PJA2,
MAN2A1
12q21.2 rs10506759 2.0 x 10-6 6.0 x 10-5 NAV3
14q32.3
3
rs4983511 5.1x10-5 8.0 x 10-6 INF2, TMEM179
16p13.2 rs11649176 5.0 x 10-6 3.6 x 10-5 RBFOX1
rs17665171 3.0 x 10-6 4.5 x 10-5 RBFOX1
rs2058528 2.0 x 10-6 6.4 x 10-5 RBFOX1
17q21.1 rs2071427 - 1.2 x 10-4 NR1D1 THRA
20q12 rs6093634 - 8.2 x 10-6 PTPRT
Xq21.31 rs5941380 2.5 x 10-7 – PCDH11X
rs35429716 3.5x10-6 – PCDH11X
*permuted
**genomic-control corrected p-values 
The TDT and case-control analyses revealed strong association at chromosomal loci 2p23.3, 
2q31.1, 3p14.1, 5q21.3, 12q21.2, 14q32.33, 16p13.2, 17q21.1, 20q12 and Xq21.31. The 
strongest association was detected at SNPs located in gene RBFOX1 at 16p13.2 and at SNP 
rs5941380 at Xq21.31. 
In the TDT test, the narrow association peak at chromosome 16p13.2 is in the RBFOX1 (RNA 
binding protein, fox-1 homolog (C. elegans) 1) gene, which is one of the largest genes in the 
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human genome. RBFOX1 is strongly expressed in the brain and it regulates tissue-specific 
splicing (Fukumura et al. 2007). Transcriptional and splicing dysregulation are the underlying 
mechanism of neuronal dysfunction in autism (Voineagu et al. 2011). In earlier studies 
RBFOX1 has been shown to be associated with several neurodevelopmental and 
neuropsychiatric disorders including ASD, mental retardation, epilepsy (Bhalla et al. 2004, 
Martin et al. 2007, Sebat et al. 2007, Wang et al. 2009, Wintle et al. 2011, Voineagu et al. 
2011), ADHD (Elia et al. 2010), bipolar disorder, and schizophrenia (Xu et al. 2008, Hamshere 
et al. 2009, Le-Niculescu et al. 2009). The most significant SNPs in our study reside around 
exon 3 (in isoform 4, UCSC). This is noteworthy, as the RNA binding domain of the protein is 
coded by these first exons. Thus, mutations in this area might affect the regulation of 
transcription of isoform 4 and exclusion of the RNA binding domain. 
PCDH11X/Y is  located in a  human XY homology region on Xq21.31 in loci  where two SNPs 
showed strong association with autism in this study (rs5941380 and rs35429716). This gene 
belongs to the protocadherin gene family, a subfamily of the cadherin superfamily. The 
PCDH11X/Y protein is involved in cell-cell recognition essential for the segmental 
development and function of the central nervous system (Kim et al. 2011). The PCDH11X
gene  has  been  linked  as  a  risk  factor  in  late  onset  Alzheimer's  disease  (Carrasquillo  et  al.  
2009). In a re-sequencing study of the X chromosome by Piton et al. (2011) one mutation 
was detected in a schizophrenia patient. Earlier, two CNVs covering parts of the PCDH11X
gene have been detected in patients with autism (Pinto et al. 2010) and three CNVs in this 
thesis, see chapter 4.3. Considering these findings, it is interesting that in this thesis, in Study 
I, the best linkage peak was detected at Xq21 near PCDH11X/Y with a different sample set.  
Suggestive associations were also detected in DTNB and NR1D1.  DTNB is  a  member of  the 
dystrophin-related  protein  family  and  is  required  for  the  maturation  or  maintenance  of  a  
subset of inhibitory synapses in the cerebellum (Grady et al. 2006). NR1D1 codes for nuclear 
receptor subfamily 1, group D, member 1, and it is one of the circadian rhythm regulating 
genes. Circadian rhythm dysfunctions are typical in ASD and mood disorders. The NR1D1 
gene has previously been reported to be associated with bipolar disorder (Kripke et al. 2009).
Finally,  we  obtained  suggestive  evidence  for  SNP  rs6093634  in  PTPRT (protein tyrosine 
phosphatase, receptor type, T) at 20q12 in the case-control analyses (P=8.2 x 10-6).   PTPRT
Results and discussion 
78
expression is restricted to the central nervous system and it is involved in both signal 
transduction and cellular adhesion in the central nervous system (McAndrew et al. 1998).  
Despite our rather restricted sample size, we were able to find statistically significant 
associations in analysis of epistasis. 244 ASD candidate genes were chosen to epistasis 
analyses (See chapter 5.4.2; selection of candidate genes). We found tentative evidence of 
epistasis for 11 SNP combinations with p-values at least 10-7. The best two associations are 
between NRXN1 and UBA52 (ubiquitin A-52 residue ribosomal protein fusion product 1). 
Epistasis interactions were also observed between genes UBA52 and TSC1 (tuberous 
sclerosis 1), RBFOX1 and SCN1A (sodium channel, voltage-gated, type I, alpha subunit), as 
well as between RBFOX3 (RNA binding protein, fox-1 homolog (C. elegans) 3) and DLG2 
(discs,  large  homolog  2  (Drosophila)).  Notably,  many  epistasis  locus  pairs  are  not  between  
the best associating genes, but also between genes which were not markedly associated in 
either the TDT or case-control analyses.  
5.4.2 Transcriptionfactorbindingsites
For TF site prediction, candidate genes were selected based on the results of association 
analyses in this study, previous studies (AutismKB database), and functions of genes related 
to synaptic formation or regulation. In total, 244 genes were selected (included in epistatic 
analyses).  From  these  244  genes,  72  gained  a  score  over  8  in  the  AutismKB  database  and  
were chosen for more refined analysis as the most plausible genes affecting autism. 
Neurospecific TF sites were predicted for 0-1  kb  upstream  of  the  genes  with  the  Match  
algorithm (TRANSFAC database) (Matys et al. 2003). The predicted TF sites were compared 
with TF sites for a random set of 210 brain expressing genes. 
TF site prediction showed differential distribution for presence of EGR binding site: it was 
found in 11.5% of candidate genes but in only 6.2 % of control genes (P=2.5x10-7). 
Transcription factors EGR1 (early growth response protein 1) and EGR3 (early growth 
response protein 3) can bind to this site. EGRs belong to “immediate early genes” (IEGs). In 
the  CNS,  IEG  transcription  factors  have  been  shown  to  contribute  to  neurite  outgrowth,  
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neurotransmitter fate, and synapse plasticity (Lyons and West 2011). It is noteworthy that 
EGR3 is functionally linked to dopamine, glutamate, and neuregulin signaling. It has been 
found in three CNV (Papanikolaou et al. 2006, Ozgen 2009, Berkel et al. 2010) and one 
linkage study of autism (Bailey et al. 1998) and is significantly associated with schizophrenia 
(Yamada et  al.  2007,  Zhang et  al.  2012)  and bipolar  disorder (Gallitano et  al.  2012).  In  our 
GWA analysis, the best associating SNP, in the promoter area of EGR3, yielded P=0.0016. We 
believe that defects in EGR transcription factors, EGR1 and EGR3, or in their expression 
might disrupt the regulation of autism-linked neuronal genes perhaps more severely than 
that of other neuronal genes. 
5.4.3 AVPR1Apromoterandassociationanalysis
Finally, we carried out a promoter analysis and an extended association analysis of the 
AVPR1A gene. AVPR1A is known to affect social communication (Donaldson and Young 2008), 
and  has  also  been  shown  to  associate  with  autism  (Kim  et  al.  2002,  Wassink  et  al.  2004,  
Yirmiya et al. 2006, Yang et al. 2010a, Yang et al. 2010b, Tansey et al. 2011). Genotyping of 
microsatellites of AVPR1A gene was performed in 205 families affected with autism, 
consisting altogether of 737 members. The phenotype was restricted to infantile autism. We 
analyzed the association of the three microsatellites AVR, RS3 and RS1 and 12 tagSNPs in the 
promoter and coding regions of AVPR1A (Figure 15). FBAT version v2.0.2c was used for the 
family-based genetic association analyses. We made a comparison of the allele lengths 
between different studies because the primers used may vary. In our study the primers used 
are  the  same  as  in  previous  studies:  Yirmiya  et  al.  (2006)  and  Ukkola  et  al.  (2009).  A  
comparison  of  the  length  and  association  results  of  the  RS1  alleles  between  this  and  
previous autism studies (Kim et al. 20020, Wassink et al. 2004, Yirmiya et al. 2006, Yang et al. 
2010a, Tansey et al. 2011) is shown in Table 9.
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The  microsatellite  locus  RS1  gave  globally  significant  P  value  with  recessive  model  (0.038,  
permuted). The strongest association of RS1 alleles was observed at allele length of 310 bp 
(P=0.018).  This  allele  has  been  shown  to  be  associated  with  autism  in  earlier  studies  
(Wassink et al. 2004, Yang et al. 2010a). In our study, we also noted several haplotypes 
which were associated with autism in our Finnish sample (Table 10). Still, the best 
associations were concentrated around the locus RS1. 
Table 10. Haplotypes of studied alleles in AVPR1A gene associated with autism in this study. 
Haplotype Additive Dominant Recessive
Markers Allele afreq Fam#* Z P** Fam#* Z P** Fam#* Z P**
RS3-AVR 4-4 0.048 33 -2.403 0.016 33 -2.319 0.021
RS3-RS1 5-2 0.046 38 2.205 0.028 38 2.114 0.033
RS1-AVR 2-3 0.022 22 2.041 0.043 22 2.041 0.039
RS1-SNP6 3-1 0.181 16 2.506 0.019
RS3-SNP6 4-1 0.070 41 -2.864 0.004 41 -2.791 0.004
SNP6-
SNP2 
2-2 0.401 18 3.033 0.002
SNP6-
SNP2 
1-1 0.597 18 -3.033 0.002
*minsize 10    **permuted   ***whole marker permutation test (chisq sum). 
SNP2=rs7307997, SNP6=rs1042615 
Notably, practically all associations found with AVPR1A are located in the promoter region of 
the gene. The promoter is polymorphic in length in all species studied so far (Hong et al. 
2009). The microsatellites RS1 and RS3, located in the promoter region have shown 
differences in relative promoter activity by allele length: shorter alleles of RS1 decrease 
AVPR1A transcription which in turn increase the amygdala activity leading to social 
withdrawal (Meyer-Lindenberg et al. 2009, Tansey et al. 2011) characteristic to the autism 
phenotype.  The  mechanism  of  how  the  microsatellite  allele  length  actually  affects  the  
transcription efficacy is not known. 
Given that the microsatellite RS1 (and a few SNPs near it) has repeatedly been associated 
with several traits including autism (Kim et al. 2002, Ukkola et al. 2009, Skuse and Gallagher 
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2011), we became interested in this region, which is a part of the AVPR1A promoter. 
Somewhat surprisingly, the promoter analysis we carried out on the AVPR1A gene with 
TRANSFAC  revealed  a  highly  likely  binding  site  of  MEF2A/MEF2C  and  PBX1-PBX3  
transcription  factors  residing  on  the  3´end  of  RS1  microsatellite.  Of  these,  MEF2C  has  
previously  been  implicated  in  autism  (Novara  et  al.  2010).  PBX2 has been reported to be 
downregulated in autism (Kuwano et al.  2011). 
MEF2 binding sites might be very important for the regulation of receptor transcription. 
Interestingly for autism, MEF2s have been shown to have direct roles in synapses: distinct 
forms  of  MEF2  TF  act  as  positive  or  negative  regulators  of  dendritic  spine  formation,  with  
MEF2C playing a key regulator role in synaptic plasticity (Li et al. 2008, Barbosa et al. 2008, 
Dietrich et al. 2012). MEF2s interact with fragile X mental retardation protein (FMRP), to 
control the excitatory synapse elimination in an activity-dependent manner (Pfeiffer et al. 
2010). MEF2C is also known to interact with MECP2, which is well known to be mutated in 
Rett syndrome (Amir et al. 1999). Moreover, MEF2C has been independently shown in 
autism and related disorders (Le Meuer et al. 2010, Zweier and Rauch 2012). Finally recent 
exome sequencing study of autism observed functional de novo mutation in MEF2C (Neale 
et al. 2012). We speculate that the relevance of MEF2C binding site in the RS1 microsatellite 
might be such that mutation(s) in the binding site sequence, or possibly, the sheer length 
differences of the microsatellite repeat adjacent to the binding site, could change the affinity 
of the transcription factor. This, in turn, could change either the magnitude of expression or 
the expression pattern of the AVP receptor in the brain, thereby affecting the brain´s ability 
to respond to AVP hormone. Obviously, functional experiments are required to confirm this 
hypothesis. 
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5.4.4 Functionalanalysis
We carried out pathway and function analysis with the IPA (Ingenuity Systems, 
www.ingenuity.com) system. The genes selected in the analyses were the same as in TF 
prediction analyses (N=72, see chapter 5.4.2). The nominally associated SNPs (P<0.001) from 
both the case-control and TDT analyses were investigated for enrichment of functions and 
pathways. The SNP results were assigned to genes within a 20 kb window. Results with no 
genes within the window were assigned to the closest genes not exceeding 1 Mb in distance. 
As result, there were 360 nominally associated genes in the case-control data.  
Despite our rather restricted sample size, the functional analyses gave biological functional 
classes which fit quite well with the functions of known autism associated genes: 
schizophrenia, expression of DNA, transactivation, development of the brain and 
morphology of embryonic tissue. Previous studies (Anney et al. 2011, Hussman et al. 2011) 
have reported the results of pathway analyses in ASD. Both of these studies observed 
enrichment of genes and processes that have previously been examined in autistic disorders 
and offer biological plausibility to these findings. 
Pathway-based methodologies are a new class of approaches to search for the underlying 
molecular mechanisms. Functional studies have revealed several candidate genes that likely 
function together, where defects in this network might cause autism. Figure 16 illustrates 
connections between the genes studied in this thesis (Studies I-IV). 
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Figure 16. Connections between genes studied in this thesis. Genes that were found to 
associate with ASD in our GWA scan (Study IV)  are colored in pink. RBFOX1 which showed 
the strongest association in our dataset is colored in red. In addition, the UBC (polyubiquitin-
C) protein is added as a hub. Black edges depict interactions acquired from the Ingenuity 
database, purple edges are based on Fogel et al. (2012). Dashed lines denote indirect proof 
of interaction. The map has been created with IPA. Proteins with no connections (according 
to IPA) were excluded. 
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5.5 Copynumbervariants(CNVs)inFinnishASDfamilies(unpublisheddata)
The results shown here are unpublished data analyzed from SNP data of the 81 ASD families 
analyzed in Study IV. In this chapter the large CNVs and CNVs containing ASD related genes 
are presented (frequency < 1% in the Finnish population). We detected an enrichment of 
large, rare deletions in ASD compared to the controls (P=0.02). This is in line with other 
published ASD studies (Pinto et al. 2010, Girirajan et al. 2011).  
We identified 120 CNVs in ASD subjects which were rare (< 1 %) in the controls. Out of these, 
73 % were previously reported in the AutismKB Database. The majority of them, 86 %, were 
inherited and 14 % were de novo. In most ASD families, inherited CNVs were transmitted 
from an apparently unaffected parent to the autistic child. Eleven of the rare CNVs were 
considered so called large-scale CNV’s (Miller et al. 2010) as they were more than 400 kb in 
size (Table 11). CNVs which contain previously reported genes in ASD are presented in Table 
12.
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One  of  the  subjects  with  infantile  autism  (3062)  had  a  large  1.1  Mb  maternally  inherited  
deletion  at  the  3p14.2  region  which  contains  the  fragile  histidine  triad  (FHIT) gene. FHIT 
deletions have recently been detected in Tourette syndrome (Fernandez et al. 2012). 
Association of 3p14.2 has been recognized in two separate studies of Asperger syndrome in 
Finnish families (Ylisaukko-oja et al. 2004, Rehnström et al. 2006). 
A large deletion of 1.6 Mb at 15q13.2-15q13 was found in this study in patient 3016 with 
infantile autism. This CNV has been previously reported in several studies (Wolpert et al. 
2000, Wassink et al. 2001, Silva et al. 2002, Keller et al. 2003, Sahoo et al. 2005, Sebat et al. 
2007, Wassink et al. 2007, Christian et al. 2008, Marshall et al. 2008, Weiss et al. 2008, 
Bremer et al. 2010, Bucan et al. 2009, Gregory et al. 2009, van der Zwaag et al. 2010, Pinto et 
al. 2010, Bremer et al. 2011, Levy et al. 2011, Sanders et al. 2011). The deletion contains the 
CHRNA7 gene. The same CNV was overlapping in ASD, schizophrenia and intellectual 
disability earlier but has also been detected in a control population (Guilmatre et al. 2009). 
Two patients with SHANK2 deletion also had a CNV covering CHRNA7 in Study III. 
Two of the patients with autism (1831 and 3063) had a large de novo deletion at the 17q12 
chromosomal region that has been reported in autistic subjects earlier. One of the genes in 
the CNV region is HNF1B (Homo sapiens HNF1 homeobox B). Patient 1831 also had diabetes. 
Interestingly, the HNF1B gene at this locus is associated in autism with renal disease or 
diabetes (Moreno-De-Luca et al. 2010, Loirat et al. 2010). 
We detected CNVs in three autistic subjects at the 22q11 region, a previously known locus 
for 22q11 deletion/DiGeorge syndrome which alters cortical circuitry and may cause 
schizophrenia, autism, attention deficit/hyperactivity disorder or intellectual disability 
(Meechan et al. 2009, Niklasson et al. 2009). One of the patients (1493) had a large, 439 kb 
paternally inherited duplication in 22q11. Two of the subjects (1908, 1925) had inherited a 
269 kb deletion and 95 kb duplication respectively at the 22q11.21 region containing genes 
PRODH and DGCR6. The 22q11 deletion spanning PRODH and DGCR6 has been detected in 
ASD, schizophrenia and ID (Guillmatre et al. 2009). These disorders share biological 
pathways and they have recurrent rearrangements in synaptic and neurodevelopmental 
genes (Guillmatre et al. 2009).  
Results and discussion 
90
In a recent study, adult patients with the 22q11.2 deletion were interviewed (Vorstman et al. 
2013). The study reported that autism in the 22q11 deletion syndrome (22q11DS) patients 
does not increase the risk for psychosis in adulthood. ASD and schizophrenia should be 
regarded as distinct phenotypic manifestations of this deletion, hence the neuropsychiatric 
phenotypic expression of the 22q11.2 deletion is truly pleiotropic (Vorstman et al. 2013). 
One 15 kb duplication at 1p33 was detected as a completely novel inherited variation 
present in the mother (1521) and her son (1518) who both have Asperger syndrome (Figure 
14). This specific CNV contains a gene, CYP4X1 (Homo sapiens cytochrome P450, family 4, 
subfamily X, polypeptide 1), which is expressed in several parts of the brain (Al-Anizy et al. 
2006).  It  is  mainly  expressed  in  neurons  in  the  brain  stem,  hippocampus,  cortex,  and  
cerebellum as well as in vascular endothelial cells (Bylund et al. 2002). The cytochrome P450 
proteins are mono-oxygenases, which catalyze many reactions involved in drug metabolism 
and the synthesis of cholesterol, steroids and other lipids. The expression pattern of CYP4X1
suggests that this protein may be involved in neurovascular functions in the brain (Bylund et 
al. 2002). We validated the CNV with qPCR (data not shown). Other members of this 
extended pedigree did not have the duplication. The grandmother as well as the aunt of the 
proband displayed some features of Asperger syndrome but their symptoms did not fulfill 
the criteria required for Asperger syndrome.  
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Figure 14. A novel inherited 15 kb duplication containing gene CYP4X1 at 1p33. The 
duplication is present only in the mother and her son with Asperger syndrome. 
Several CNVs found in this study overlapped with schizophrenia, ID, ADHD and anxiety 
disorders (Guilmatre et al. 2009, Fernandez et al. 2012, Elia et al. 2011).  We detected 
several copy number variations that most likely are predisposing to autism, because they 
either arose de novo and/or overlapped with known micro-deletions and –duplications or 
they included genes which are important for synaptic functions and were not found in the 
normal  population.  Previously  known  ASD  related  genes  which  are  located  in  the  CNV  
regions detected in this study and whose exonic regions were covered with CNV included 
DISC1, FOXG1, ASMT, PCDH11X, GSTM1, GFAP and PRODH (Table 12). 
Notably,  a  male  patient  (1869)  had  a  102  kb  maternally  inherited  DISC1 duplication. This 
patient had autism, epilepsy, and aggressive behavior. DISC1 (disrupted in schizophrenia 1) 
codes the protein involved in neurite outgrowth and cortical development. DISC1 is related 
to schizophrenia, bipolar disorder, and ASD (Millar et al. 2000, Ekelund et al. 2001, 
Hodgkinson et al. 2004, Kilpinen et al. 2008). 
Finally, a girl had a paternally inherited 303 kb duplication at FOXG1. The phenotype was 
characterized by severe delay in psychomotor development and communication skills, 
psychotic behavior, and echolaly. The diagnosis was disintegrative disorder (F84.3). 
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Mutations in FOXG1 (forkhead box G1) have previously been detected in atypical Rett 
syndrome  (Florian  et  al.  2011).  The  FOXG1 gene encodes a winged-helix transcriptional 
repressor which is essential for the development of the ventral telencephalon in the 
embryonic forebrain. Reported aberrations of FOXG1 include point mutations, translocation, 
duplication,  and  a  large  deletion  on  chromosome  14q12  (Florian  et  al.  2011).  Affected  
individuals with FOXG1 mutations have shown dysmorphic features and a Rett-like clinical 
course, including normal perinatal period, post natal microcephaly, seizures, and severe 
mental retardation (Florian et al. 2011). The majority of patients with duplications on 14q12 
containing FOXG1 have developmental epilepsies, mental retardation, severe speech 
impairment, and infantile spasms (Brunetti-Pierri et al. 2011). Phenotypes differ presumably 
due to the varying size of the duplication. 
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6 CONCLUDINGREMARKSANDFUTUREPROSPECTS
In the past decade, considerable efforts towards understanding the nature of ASD have been 
undertaken. Rapidly evolving genomic technologies have produced enormous advances in 
the genetics of ASD. Furthermore, the increasing amount of international, large study 
cohorts which combine ASD samples and scientific knowledge from research groups from all 
over the world has led highly reproducible findings.  
In this thesis, the major finding was the strong association of the RBFOX1 gene in the Finnish 
sample set. In future, the data will be combined with large, international data where some 
hints of association of RBFOX1 have been observed. The replication of the GWA study in a 
bigger sample set might reveal genome-wide significant association of this gene if the 
associated SNPs are the same in these two different data sets.  We will also perform 
haplotype analyses of RBFOX1 and if the association remains, the whole gene will be 
sequenced.  In  this  thesis,  two  SNPs  in  the  GWA  scan  showed  significant  association  with  
autism in the same locus Xq21, which was observed in our X-chromosomal linkage analysis 
earlier (Study I). Further analysis of haplotypes and homozygosity of common SNPs in this 
region could reveal X-linked recessive candidate variants that may be found in the isolated 
Finnish population.  
Promoter analyses of autism candidate genes revealed the other important findings in this 
thesis. We observed that TF binding sites for EGR was enriched in autism candidate genes. 
Furthermore, a MEF2C binding site on the promoter region of the AVPR1A gene was located 
on the RS1 allele, which has shown association with autism in several studies, including ours. 
That might partly explain the association of the RS1 allele with autism. Cell biological studies 
are warranted to confirm the significance of these findings. Promoter analysis to predict 
transcription binding sites gives important information about the regulation of genes 
contributing to ASD. Next generation sequencing of the Finnish ASD samples would provide 
important information of the promoter regions in ASD. 
In Study III of this thesis, we detected harmful mutations in the SHANK2 gene which reduced 
synaptic density in vitro. Patients who had a deletion of SHANK2 carried additional CNVs on 
chromosomal region 15q11-q13, previously associated in ASD and several other 
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neuropsychiatric disorders. This and previous studies suggest a multiple hit model for ASD. 
More studies are warranted to analyze what kind of combinations of genetic defects will be 
detected in the individual ASD families. In this thesis, we also performed a functional analysis 
of ASD related genes with IPA. The functional classes most significantly enriched in ASD were 
related to schizophrenia and development of the brain. We also observed connections 
between several genes studied in this thesis (Figure 16). It is probable that the defects on 
the network of ASD related genes cause the disorder, which again suggests a multiple hit 
model in ASD. 
Rare variants have been under extensive study in the last few years in ASD. Large structural 
variants are present in 5-10 % of ASD cases.  It is estimated that there are more than 200 
CNV loci which predispose to ASD in the human genome. Each individual CNV is rare and 
accounts for  less  than 1 % of  all  cases of  ASD.  Large CNVs (>400 kb)  which contain exonic  
regions of ASD candidate genes are likely to predispose to ASD. The same CNVs have been 
detected in ASD and other neuropsychiatric disorders such as ADHD, epilepsy, schizophrenia 
and intellectual disability.  CNVs in ASD have been detected recurrently in chromosomal 
regions 15q13.3, 16p11.2, 17q12 and 22q11. We detected CNVs in our Finnish ASD sample in 
all of the aforementioned locations.  CNVs detected in the ASD sample often also occur in 
unaffected individuals, although with lower frequency. Hence, it seems that none of the 
single CNVs are fully penetrant and it remains unsolved how many other predisposing 
genetic variants are sufficient to cause ASD. 
Exome sequencing studies have revealed that non-synonymous de novo mutations are 
enriched in affected individuals. The results of exome sequencing studies together with CNV 
data indicate extensive locus heterogeneity but also provide a target for future diagnostics 
and therapeutics. Rare genetic causes for a disease could provide important knowledge for 
individual families. Another question is if the rare variants, even though they pinpoint to 
synaptic genes, are sufficient to cause ASD. It is conceivable that additional genetic variants 
and possibly triggering environmental factors are needed to cause autism. Much more 
information is coming in the next few years when next generation sequencing projects will 
publish more results.  
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Future  work  will  have  to  investigate  how  all  the  rare  and  common  predisposing  variants  
interact together and with environmental factors. ASD comprise a broad range of variation 
in  the  severity  of  symptoms,  from  patients  requiring  special  education  and  complete  daily  
care to individuals with exceptional occupational skills. Considering the well characterized,
large  chromosomal  aberrations  known  to  predispose  to  ASD,  it  may  be  beneficial  for  
individual families to get that information. It would decrease parental feelings of guilt and 
make it easier to estimate the recurrence risk for future children and other family members. 
There is no cure for autism yet and much more information has to be gathered from brain 
functions before we even get close to understanding the mechanisms of autism. 
Nevertheless, evidence of family-specific, rare genetic events such as mutations and de novo 
CNVs is accumulating. Exome sequencing and next qeneration sequencing studies will reveal 
much more evidence for this field in the next few years. Future studies will aim to translate 
genomic findings into molecular mechanisms. This information will be helpful for drug 
development which could specifically target these impaired molecular mechanisms.
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